Controlled release liquid active agent formulation dosage forms

ABSTRACT

Controlled release of liquid, active agent formulations is provided by dispersing porous particles containing the liquid active agent formulation in osmotic, push-layer dosage forms. The dosage forms may provide for continuous or pulsatile delivery of active agents.

This application claims the priority of provisional application No.60/113,559, filed Dec. 23, 1998, which is incorporated herein byreference.

FIELD OF THE INVENTION

This invention pertains to the controlled delivery of pharmaceuticalagents and dosage forms therefor. In particular, the invention isdirected to improved methods, dosage forms and devices for thecontrolled delivery of liquid active agent formulations to anenvironment of use.

BACKGROUND OF THE INVENTION

Administration of liquid, active agent formulations is often preferredover solid active agent formulations in order to facilitate absorptionof the active agent and obtain a beneficial effect for the intended usein the shortest possible time after the formulation is exposed to theenvironment of use. Examples of prior art devices to deliver liquid,active agent formulations are soft gelatin capsules that contain aliquid active agent formulation or liquid formulations of the activeagent that are bottled and dispensed in measured dosage amounts by thespoonful, or the like. Those systems are not generally amenable tocontrolled delivery of the active agent over time. While it is desiredto have the active agent exhibit its effect as soon as it is released tothe environment of use, it also often is desirable to have controlledrelease of the active agent to the environment of use over time. Suchcontrolled release may be sustained delivery over time, such as zeroorder, or patterned delivery, such as pulsatile for example. Prior artsystems have not generally been suitable for such delivery.

Various devices and methods have been described for the continuousdelivery of active agents over time. Typically, such prior art systemshave been used to deliver active agents initially in the dry state priorto administration. For example, U.S. Pat. Nos. 4,892,778 and 4,940,465,which are incorporated herein by reference, describe dispensers fordelivering a beneficial agent to an environment of use that include asemipermeable wall defining a compartment containing a layer ofexpandable material that pushes a drug layer out of the compartmentformed by the wall. The exit orifice in the device is substantially thesame diameter as the inner diameter of the compartment formed by thewall.

U.S. Pat. No. 4,915,949, which is incorporated herein by reference,describes a dispenser for delivering a beneficial agent to anenvironment of use that includes a semipermeable wall containing a layerof expandable material that pushes a drug layer out of the compartmentformed by the wall. The drug layer contains discrete tiny pillsdispersed in a carrier. The exit orifice in the device is substantiallythe same diameter as the inner diameter of the compartment formed by thewall.

U.S. Pat. No. 5,126,142, which is incorporated herein by reference,describes a device for delivering an ionophore to livestock thatincludes a semipermeable housing in which a composition containing theionophore and a carrier and an expandable hydrophilic layer is located,along with an additional element that imparts sufficient density to thedevice to retain it in the rumen-reticular sac of a ruminant animal, Theionophore and carrier are present in a dry state during storage and thecomposition changes to a dispensable, fluid-like state when it is incontact with the fluid environment of use. A number of different exitarrangements are described, including a plurality of holes in the end ofthe device and a single exit of varying diameter to control the amountof drug released per unit time due to diffusion and osmotic pumping.

It is often preferable that a large orifice, from about 50%-100% of theinner diameter of the drug compartment, be provided in the dispensingdevice containing the active agent and a bioerodible or degradableactive agent carrier. When exposed to the environment of use, drug isreleased from the drug layer by erosion and diffusion. In those caseswhere the drug is present in the solid state, the realization of thebeneficial effect is delayed until the drug is dissolved in the fluidsof the environment of use and absorbed by the tissues or mucosalenvironment of the gastrointestinal tract. Such delay often is nottolerable. Also, for drugs that are poorly soluble in gastric orintestinal fluids, the delay may be further exacerbated.

Devices in which the drug composition initially is dry but in theenvironment of use is delivered as a slurry, suspension or solution froma small exit orifice by the action of an expandable layer are describedin U.S. Pat. Nos. 5,660,861, 5,633,011; 5,190,765; 5,252,338; 5,620,705;4,931,285; 5,006,346; 5,024,842; and 5,160,743. Typical devices includean expandable push layer and a drug layer surrounded by a semipermeablemembrane.

When the active agent is insoluble or poorly soluble, prior art systemsmay not provide rapid delivery of active agent or concentrationgradients at the site of absorption that facilitate absorption throughthe gastrointestinal tract. Various approaches have been put forth toaddress such problems, including the use of water-soluble salts,self-emulsifying compositions, polymorphic forms, powdered solutions,molecular complexes, micronization, eutectics, and solid solutions. Anexample of the use of a powdered solution is described by Sheth, et al.,in “Use of Powdered Solutions to Improve the Dissolution Rate ofPolythiazide Tablets,” Drug Development and Industrial Pharmacy, 16(5),769-777 (1990). References to certain of the other approaches are citedtherein. Additional examples of powdered solutions are described in U.S.Pat. No. 5,800,834. The patent describes methodology for calculating theamount of liquid that may be optimally sorbed into materials to preventthe drug solution from being exuded from the granular composition duringcompression.

U.S. Pat. No. 5,486,365, which is incorporated herein by reference,describes a spheronized material formed from a scale-like calciumhydrogen phosphate particulate material having a high specific surfacearea, good compressibility and low friability. That patent indicatesthat the material has the characteristic of high liquid absorption.However, the patent does not suggest that the material may be used as acarrier for delivery of a liquid medicament formulation to theenvironment of use. Instead, the patent describes the formation of adried formulation, such as formed by spray drying. The patent describesthe use of a suspension containing medicines and binders during thespray-drying granulation process to form a spherical particle containingthe medicine. As an example, ascorbic acid in an amount equivalent to10% of the scale-like calcium hydrogen phosphate was dissolved into aslurry of 20 weight percent of calcium hydrogen phosphate in water, andthe resulting slurry was spray dried to form dried, spherical calciumhydrogen phosphate containing ascorbic acid. That material was thentableted under loads of 500-2000 kg/cm².

SUMMARY OF THE INVENTION

It has been surprisingly discovered that certain absorbent materialshaving prescribed physical characteristics, as exemplified by, forexample, particular porous calcium hydrogen phosphate powders describedin U.S. Pat. No. 5,486,365, sold under the trademark FujiCalin®, andmagnesium aluminometasilicate powders, sold under the trademarkNeusilin™ (Fuji Chemical Industries (U.S.A.) Inc., Robbinsville, N.J.),may be used to prepare dosage forms in which liquid, active agentformulations may be sorbed into the interior pores of the aforementionedmaterials in significant amounts and delivered to the site ofadministration in the liquid state. It has further been surprisinglydiscovered that such types of porous particles with liquid, active agentformulations sorbed into the particles may be fabricated into controlledrelease dosage forms without exuding the liquid, active agentformulation out of the particles during the manufacturing process. Thatdiscovery has permitted the fabrication of controlled release dosageforms that provided for the delivery of the active agent to the deliverysite in the liquid state, thus providing minimal delay in the onset ofthe desired beneficial effect of the active agent, since the activeagent does not have to be initially dissolved or dispersed in the formof microparticles at the site of action. Furthermore, such dosage formsmay permit large concentration gradients of active agent in solution,and optional delivery of absorption enhancers, at the absorption site tofacilitate absorption of the active agent. Microcrystalline cellulose,porous sodium carboxymethyl cellulose crosslinked sold as Ac-Di-Sol (FMCCorporation), porous soy bean hull fiber sold as Fl-1 Soy Fiber (FibredGroup), and silicon dioxide having high surface area and good absorptionproperties may also be used in the dosage forms described herein.However, the calcium hydrogen phosphate and magnesiumaluminometasilicate particles as described herein are presentlypreferred.

Accordingly, in one aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being adapted to resist compaction forces sufficient toform a compacted drug layer without significant exudation of the liquid,active agent formulation. Optionally, a flow-promoting layer may beinterposed between the inner surface of the wall and at least theexternal surface of the drug layer located within the cavity. Also, aplacebo layer to delay onset of delivery of the active agent optionallymay be placed between the drug layer and the exit orifice.

In another aspect, the invention comprises a dosage form for an activeagent comprising a wall defining a cavity, the wall having an exitorifice formed or formable therein and at least a portion of the wallbeing semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles, having a mean particle size of 50-150 microns, beingformed by spray drying a scale-like calcium hydrogen phosphate with aspecific surface area of 20 m²/g to 60 m²/g, an apparent specific volumeof 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g or more, aprimary particle size of 0.1μ to 5μ, and an average particle size of 2μto 10μ among secondary particles that are aggregates of the primaryparticles, the scale-like calcium hydrogen phosphate being representedby the following general formula:

CaHPO₄.mH₂O

wherein m satisfies the relationship 0≦m≦2.0.

In yet another aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being calcium hydrogen phosphate having a specificvolume of at least 1.5 ml/g, a BET specific surface area of at least 20m²/g, and a water absorption capacity of at least 0.7 ml/g. Preferably,the particles have a bulk density of 0.4-0.6 g/ml, a BET surface area of30-50 m²/g, a specific volume of greater than 2 ml/g, and a mean poresize of at least 50 Angstroms.

In another aspect, the invention comprises a dosage form for an activeagent comprising a wall defining a cavity, the wall having an exitorifice formed or formable therein and at least a portion of the wallbeing semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being calcium hydrogen phosphate having a specificvolume of at least 1.5 ml/g, a BET specific area of at least 20 m²/g,and a water absorption capacity of at least 0.7 ml/g, the particleshaving a size distribution of 100% less than 40 mesh, 50%-100% less than100 mesh and 10%-60% less than 200 mesh. Preferably, 100% is less than40 mesh, 60%-90% is less than 100 mesh and 20%-60% is less than 200mesh.

In yet another aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being calcium hydrogen phosphate having a bulk specificvolume of 1.5 ml/g-5 ml/g, a BET specific area of 20 m²/g-60 m²/g, awater absorption capacity of at least 0.7 ml/g, and a mean particle sizeof at least 70 micrometers.

In still another aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being adapted to resist compaction forces sufficient toform a compacted drug layer without significant exudation of the liquid,active agent formulation, the dosage form optionally comprising aplacebo (inert) layer between the exit orifice and the drug layer.Optionally, a flow-promoting layer may be interposed between the innersurface of the wall and at least the external surface of the drug layerlocated within the cavity.

In yet another aspect, the invention comprises a method of facilitatingthe release of an active agent from a dosage form comprising sorbing aliquid formulation of the active agent into a plurality of porousparticles, the particles, having a mean particle size of 50-150 microns,being formed by spray drying a scale-like calcium hydrogen phosphatewith a specific surface area of 20 m²/g to 60 m²/g, an apparent specificvolume of 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g ormore, a primary particle size of 0.1μ to 5μ, and an average particlesize of 2μ to 10μ among secondary particles that are aggregates of theprimary particles, the scale-like calcium hydrogen phosphate beingrepresented by the following general formula:

CaHPO₄.mH₂O

wherein m satisfies the relationship 0≦m≦2.0, and dispersing theparticles throughout a bioerodible carrier.

In another aspect, the invention comprises a composition comprising aliquid formulation of the active agent sorbed into a plurality of porousparticles, the particles, having a mean particle size of 50-150 microns,being formed by spray drying a scale-like calcium hydrogen phosphatewith a specific surface area of 20 m²/g to 60 m²/g, an apparent specificvolume of 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g ormore, a primary particle size of 0.1μ to 5μ, and an average particlesize of 2μ to 10μ among secondary particles that are aggregates of theprimary particles, the scale-like calcium hydrogen phosphate beingrepresented by the following general formula:

CaHPO₄.mH₂O

wherein m satisfies the relationship 0≦m≦2.0, and dispersed throughout abioerodible carrier, the particles being released in the environment ofuse over a prolonged period of time.

In yet another aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being magnesium aluminometasilicate.

In still another aspect, the invention comprises a dosage form for anactive agent comprising a wall defining a cavity, the wall having anexit orifice formed or formable therein and at least a portion of thewall being semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being magnesium aluminometasilicate represented by thegeneral formula

Al₂O₃MgO.2SiO₂.nH₂O

wherein n satisfies the relationship 0≦n≦10.

In another aspect, the invention comprises a dosage form for an activeagent comprising a wall defining a cavity, the wall having an exitorifice formed or formable therein and at least a portion of the wallbeing semipermeable; an expandable layer located within the cavityremote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles being magnesium aluminometasilicate represented by thegeneral formula

Al₂O₃MgO.2SiO₂.nH₂O

wherein n satisfies the relationship 0≦n≦10 and having a specificsurface area of about 100-300 m²/g, an oil absorption capacity of about1.3-3.4 ml/g, a mean particle size of about 1-2 microns, an angle ofrepose about 25°-45°, a specific gravity of about 2 g/ml and a specificvolume of about 2.1-12 ml/g.

The dosage forms of the invention may be fabricated with inert spacersbetween one or more drug layers to provide for pulsatile drug deliveryor with a plurality of drug layers, each having a different activeagent. Different active agents may be included within a single druglayer.

Generally, 5% and up to 70%, more often 20-70%, preferably 30-60%, andmore preferably 40-60%, by weight of the liquid, active agentformulation may be loaded into the porous particles. Up to about 50% byweight of liquid active agent formulation may be loaded into the porouscrystalline materials, such as calcium hydrogen phosphate particles, butmore typically 30-40 weight percent. Higher loading is possible withamorphous porous carriers such as magnesium aluminometasilicates, whichmay contain up to 60-70% liquid, active agent formulation, more usuallyup to 60%. A small amount of a binder, e.g. up to 5-10% by weight, maybe added to form the active agent layer with calcium hydrogen phosphateparticles, as well as a tableting lubricant. For amorphous materials,usually less or no binder and lubricant are used. Blends of the variousabsorptive materials described herein may be used, such as for example,blends of crystalline material such as calcium hydrogen phosphate withthe amorphous material such as magnesium aluminosilicate.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a porous particle containing a liquid, active agentformulation utilized in the present invention;

FIG. 2 illustrates a composition comprising a plurality of particlescontaining liquid, active agent formulation as illustrated in FIG. 1dispersed in a carrier and suitable for use in the dosage forms of theinvention;

FIG. 3 illustrates a dosage form of this invention adapted for zeroorder release of active agent;

FIG. 4 illustrates a dosage form of this invention adapted to deliver adelayed pulse of the active agent;

FIG. 5 illustrates the release profile (cumulative release as a functionof time) of the active agent progesterone from a representative dosageform of the invention having zero order release rate;

FIGS. 6-10 illustrate the release profile (percent of active agentreleased as a function of time) of the active agent progesterone forrepresentative dosage forms of the invention having a delayed pulserelease, wherein the initial delay is 2 hours, 3 hours, 4-5 hours, 6-7hours and about 10 hours for the dosage forms described in Examples 2,3, 4, 5 and 6, respectively;

FIG. 11 presents the dissolution profiles in artificial gastric fluid ofseveral different drug layer formulations prepared with calcium hydrogenphosphate as described in Example 7;

FIG. 12 presents the dissolution profiles in artificial intestinal fluidof several different drug layer formulations prepared with magnesiumaluminometasilicate powders as described in Example 7;

FIG. 13 presents release rate profiles of several pulse dosage formshaving different periods of delay prepared with magnesiumaluminometasilicate powders as described in Example 7; and

FIG. 14 presents release rate profiles of several pulse dosage formsprepared with automatic tableting equipment and illustrating the effectof membrane weight on the delay period as described in Example 8.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is best understood by reference to the followingdefinitions, the drawings and exemplary disclosure provided herein.

Definitions

By “active agent”, “drug”, or “compound”, which are used interchangeablyherein, is meant an agent, drug, compound, composition of matter ormixture thereof which provides some physiological, psychological,biological, or pharmacological, and often beneficial, effect when in theenvironment of use.

By “uniform rate of release” or “uniform release rate” is meant a rateof release of the active agent from a dosage form that does not varypositively or negatively by more than 30% from the mean rate of releaseof the active agent over a prolonged period of time, as determined in aUSP Type 7 Interval Release Apparatus. Preferred uniform rates ofrelease will vary by not more than 25% (positively or negatively) fromthe mean rate of release determined over a prolonged period of time.

By “prolonged period of time” or “prolonged period” is meant acontinuous period of time of 4 hours or more, more typically 6 hours ormore.

By “dosage form” is meant a pharmaceutical composition or devicecomprising an active pharmaceutical agent, the composition or deviceoptionally containing inactive ingredients, such aspharmaceutically-acceptable carriers, excipients, suspension agents,surfactants, disintegrants, binders, diluents, lubricants, stabilizers,antioxidants, osmotic agents, colorants, plasticizers, and the like,that are used to manufacture and deliver active pharmaceutical agents.

By “pharmaceutically-acceptable acid addition salt” or“pharmaceutically-acceptable salt”, which are used interchangeablyherein, are meant those salts in which the anion does not contributesignificantly to the toxicity or pharmacological activity of the salt,and, as such, they are the pharmacological equivalents of the bases ofthe compounds to which they refer. Examples of pharmaceuticallyacceptable acids that are useful for the purposes of salt formationinclude but are not limited to hydrochloric, hydrobromic, hydroiodic,citric, acetic, benzoic, mandelic, fumaric, succinic, phosphoric,nitric, mucic, isethionic, palmitic, and others.

By “sustained release ” is meant continuous release of active agent toan environment of use over a prolonged period.

By “pulsatile release” is meant release of an active agent to anenvironment of use for one or more discrete periods of time preceded orfollowed by (i) at least one discrete period of time in which the activeagent is not released, or (ii) at least one period of time in whichanother, different active agent is released. Pulsatile release is meantto include delayed release of active agent following administration ofthe dosage form and release in which one or more pulses of active agentare released over a period of time.

By “steady state” is meant the condition in which the amount of drugpresent in the blood plasma of a subject does not vary significantlyover a prolonged period of time.

By “release rate assay” is meant a standardized assay for thedetermination of a compound using a USP Type 7 interval releaseapparatus substantially in accordance with the description of the assaycontained herein. It is understood that reagents of equivalent grade maybe substituted in the assay in accordance with generally-acceptedprocedures. Also, different fluids such as artificial gastric fluid orartificial intestinal fluid may be used to evaluate releasecharacteristics in environments characterized by different pH values.

By “liquid, active agent formulation” is meant that the active agent ispresent in a composition that is miscible with or dispersible in thefluids of the environment of use, or is able to flow or diffuse from thepores of the particles into the environment of use. The formulation maybe neat, liquid active agent, or a solution, suspension, slurry,emulsion, self-emulsifying composition, colloidal dispersion or otherflowable composition in which the active agent is present.

The active agent may be accompanied by a suspension agent, antioxidant,emulsion former, protecting agent, permeation enhancer and the like. Theamount of an active agent in a dosage form generally is about 0.05 ng to5 g or more, with individual dosage forms comprising, for example, 25ng, 1 mg, 5 mg, 10 mg, 25 mg, 100 mg, 250 mg, 500 mg, 750 mg, 1.0 g, 1.2g, and the like, of active agent. The system typically can beadministered once, twice or thrice daily for pharmaceuticalapplications, or more or less as required by the particular application.In agricultural applications, systems typically will be applied atlonger intervals, such as weekly, monthly, seasonally or the like.

One of the most suitable devices for the controlled release of liquidactive agent formulations in accordance with this invention is thathaving a semipermeable wall defining a compartment, an expandable pushlayer and a drug layer in the compartment, and an exit orifice formed inthe dosage form to permit the drug layer to be dispensed. Within thedrug layer is a carrier in which is dispersed a plurality of porousparticles in which the liquid, active agent has been sorbed. As the pushlayer expands, the carrier comprising the drug layer will be forced fromthe dosage form substantially in the dry state where it will erode andrelease the porous particles containing the liquid, active agentformulation. After release, the liquid active agent formulation will beimmediately available the environment of use in the liquid state, andthe porous particles will themselves disintegrate or erode and furtherrelease the active agent formulation.

When manufacturing such dosage forms, a common practice is to fabricatea compressed tablet comprising the drug layer and the push layer.Typically, the drug layer composition, conveniently in granulated orpowdered form, is compressed in a die cavity of a vertical tablettingpress. Then the push layer composition, also conveniently in granular orpowdered form, is placed in the die cavity above the drug layer andcompressed as well to form a bilayer tablet. During the compression orcompacting step of the drug layer, the porous particles should besufficiently resistant to the compressive forces so as not to be crushedor pulverized to any significant extent and prematurely release theliquid, active agent formulation from the porous particles.

Materials useful for sorbing the liquid, active agent formulations areporous particulates that are characterized by high compressibility ortensile strength to withstand compacting forces applied duringcompacting steps and minimize exudation of liquid, active agentformulation from the pores; particle flow characteristics that allow forthe porous particles to be directly compacted without the use of abinder or with minimal use of a binder; low friability so as to precludeor minimize exudation of the liquid and facilitate tablet cohesion,active agent formulation from the particles during compacting steps; andhigh porosity so as to absorb an adequate of amount of a liquid, activeagent formulation to provide an effective amount of active agent in adosage form. The particles should be adapted to absorb an amount ofliquid, active agent formulation such that a therapeutically effectiveamount of the active agent may be delivered in a unitary dosage formthat is of a size that can be conveniently swallowed by a subject and,preferably provided in four or fewer tablets or capsules for ingestionat the same time. The porosity of the particles may be such that atleast 5% and up to 70%, more often 20-70%, preferably 30-60%, and morepreferably 40-60%, by weight of the liquid, active agent formulation,based on weight of the particles may be sorbed into the pores of theparticles, while the particles exhibit sufficient strength at suchdegree of active agent loading so as not to significantly be crushed orpulverized by compacting forces to which the particles will be subjectedduring manufacturing operations. More typically, the liquid, activeagent formulation may comprise 30-40% of the weight of the porousparticles when the particles are crystalline, such as calcium hydrogenphosphate, but that percentage may be greater, e.g., up to 60-70% ormore when more amorphous materials, such as magnesiumaluminometasilicates, are used. Blends of crystalline and amorphousmaterial may be utilized. At high loadings, it may be advantageous touse blends of calcium hydrogen phosphate particles and amorphousmagnesium aluminometasilicate powders.

Preferred materials are those having a strength to resist compressionforces of greater than 1500 kg/cm² without substantial exudation of theliquid, active agent formulation, and most preferably without the tablethardness plateauing.

A particularly suitable porous particle is exemplified by the particularform of calcium hydrogen phosphate described in U.S. Pat. No. 5,486,365,which is incorporated herein by reference. As described therein, calciumhydrogen phosphate is prepared by a process yielding a scale-likecalcium hydrogen phosphate that can be represented by the formulaCaHPO₄.mH₂O wherein m satisfies the expression 0≦m≦0.5. Useful calciumhydrogen phosphate materials may include those of the formulaCaHPO₄.mH₂O wherein m satisfies the expression 0≦m≦2.0. The scale-likecalcium hydrogen phosphate produced has characteristic physicalproperties that make it particularly suitable for use in the presentinvention. The scale-like material provides high specific surface area,high specific volume, high capacity for water and oil absorption, andthe ability to readily form into spheres upon spray drying. Thespherical particulates have excellent flow properties and permit directcompaction into tablets without binders and without significant crushingor pulverizing of the particles during the compaction step.

The scale-like calcium hydrogen phosphate particles generally have a BETspecific surface area of at least 20 m²/g, typically 20 m²/g-60 m²/g, aspecific volume of at least 1.5 ml/g, typically 2-5 ml/g or more, and anoil and water absorption capacity of at least 0.7 ml/g, typically0.8-1.5 ml/g. When formed into spheres the spherical particulates mayhave a mean particle size a mean particle size of 50 microns or greater,usually about 50-150 microns, and often about 60-120 microns. Theparticle size distribution may be 100% through 40 mesh, 50%-100% through100 mesh, and 20%-60% through 200 mesh. The bulk density may be fromabout 0.4 g/ml-0.6 g/ml.

A most preferred form of calcium hydrogen phosphate is that sold underthe trademark FujiCalin® by Fuji Chemical Industries (U.S.A.) Inc.,Robbinsville, N.J., in types SG and S. Typical parameters for thatmaterial include a mean particle size of 500-150 microns, a mean poresize on the order of 70 Angstroms, a specific volume of about 2 ml/g, aBET specific surface area of about 30-40 m²/g, and an oil and waterabsorption capacity of about 0.7 ml/g. Type SG typically will have amean particle size of about 113 microns, and a particle sizedistribution of 100% through 40 mesh, 60% through 100 mesh and 20through 200 mesh. Type S typically will have a mean particle size ofabout 68 microns, and a particle size distribution of 100% through 40mesh, 90% through 100 mesh and 60% through 200 mesh. Mixtures of the twotypes may be conveniently employed to provide particulates havingphysical characteristics that are suitable for various applications, asmay be determined by those skilled in the art of pharmaceuticalformulation, tableting and manufacturing.

The calcium hydrogen phosphate has low friability, demonstrating atensile strength of up to about 130 kg/cm² when subjected to compressiveforces of up to 3000 kg/cm². The hardness of the tableted material tendsnot to plateau at compression forces to that limit, while materials suchas microcrystalline cellulose (Avicel PH 301), lactose, DI-TAB and KyowaGS tend to plateau at or about 700-1500 Kg/cm². The angle of repose forthe preferred materials typically is on the order of 32-35 degrees.

Another material that may be utilized is that formed of magnesiumaluminometasilicate which may be represented by the general formula

Al₂O₃MgO.2SiO₂.nH₂O

wherein n satisfies the relationship 0≦n≦10. Commercially availablemagnesium aluminometasilicates are sold as Grades S₁, SG₁, UFL₂, US₂,FH₁, FH₂, FL₁, FL₂, S₂, SG₂, NFL₂N, and NS₂N, under the trademarkNeusilin™ by Fuji Chemical Industries (U.S.A.) Inc., Robbinsville, N.J.Especially preferred grades are S₁, SG₁, US₂ and UFL₂, with US₂presently being most preferred. Those materials which are amorphoustypically have a specific surface area (arca) of about 100-300 m²/g, anoil absorption capacity of about 1.3-3.4 ml/g, a mean particle size ofabout 1-2 microns, an angle of repose about 25°-45°, a specific gravityof about 2 g/ml and a specific volume of about 2.1-12 ml/g.

Other absorptive materials may be substituted for the foregoing orblended therewith, such as for example, powders of microcrystallinecellulose sold under the tradenames Avicel (FMC Corporation) and Elcema(Degussa); porous sodium carboxymethyl cellulose crosslinked sold asAc-Di-Sol (FMC Corporation); porous soy bean hull fiber sold under thetradename Fl-1 Soy Fiber (Fibred Group); and porous agglomerated silicondioxide, sold under the tradenames Cab-O-Sil (Cabot) and Aerosil(Degussa).

The liquid, active agent formulation may be in any form that can bedispensed from the inside of the pores as the drug layer disintegratesin the environment of use. The formulation, for example, may be neat,liquid active agent, liquid active agent in a solution, suspension,emulsion or self-emulsifying composition, or the like, or a liposomalsolution or solid formulation, or solid active agent in solution,suspension or slurry. Optionally other dosage-forming ingredients, suchas an anti-oxidant, a suspending agent, a surface active agent, and thelike may be present in the liquid, active agent formulation. The liquid,active agent formulation will be released in a form most suitable toprovide active agent to the site of delivery in a state in which it maybe rapidly absorbed in the environment of use to provide its beneficialaction with minimum delay once delivered to the absorption site.

It often is desirable to provide the dosage form with a flow-promotinglayer or lubricant that facilitates complete release of the drug layerfrom the compartment formed by the semipermeable wall since the formedbilayer tablet may be formed with surface irregularities that impede therelease of the drug layer from the dosage form and sometimes results inincomplete release of the drug layer.

Dosage forms of this invention release effective amounts of active agentto the patient over a prolonged period of time and often provide theopportunity for less frequent dosing, including once-a-day dosing, thanpreviously required for immediate release compositions. The dosage formsof this invention comprise a composition containing a liquid, activeagent formulation contained in porous particles dispersed in abioerodible carrier.

Active agents include, inter allia, foods, food supplements, nutrients,drugs, antiacids, vitamins, microorganism attenuators and other agentsthat provide a benefit in the environment of use and may be dissolved,suspended or otherwise dispersed in a liquid to form a liquid, activeagent formulation. Active agents include any physiologically orpharmacologically active substance that produces a localized or systemiceffect or effects in animals, including warm blooded mammals, humans andprimates; domestic household or farm animals such as cats, dogs, sheep,goats, cattle, horses and pigs; laboratory animals such as mice, ratsand guinea pigs; zoo and wild animals; and the like. Active agents thatcan be delivered include inorganic and organic compounds, including,without limitation, active agents which act on the peripheral nerves,adrenergic receptors, cholinergic receptors, the skeletal muscles, thecardiovascular system, smooth muscles, the blood circulatory system,synoptic sites, neuroeffector junctional sites, endocrine and hormonesystems, the immunological system, the reproductive system, the skeletalsystem, autacoid systems, the alimentary and excretory systems, thehistamine system and the central nervous system.

Suitable active agents may be selected from, for example, proteins,enzymes, enzyme inhibitors, hormones, polynucleotides, nucleoproteins,polysaccharides, glycoproteins, lipoproteins, polypeptides, steroids,hypnotics and sedatives, psychic energizers, tranquilizers,anticonvulsants, antidepressants, muscle relaxants, antiparkinsonagents, analgesics, anti-inflammatories, antihystamines, localanesthetics, muscle contractants, antimicrobials, antimalarials,antivirals, antibiotics, antiobesity agents, hormonal agents includingcontraceptives, sympathomimetics, polypeptides and proteins capable ofeliciting physiological effects, diuretics, lipid regulating agents,antiandrogenic agents, antiparasitics, neoplastics, antineoplastics,antihyperglycemics, hypoglycemics, nutritional agents and supplements,growth supplements, fats, ophthalmics, antienteritis agents,electrolytes and diagnostic agents.

Examples of particular active agents useful in this invention includeprochlorperazine edisylate, ferrous sulfate, atbuterol, aminocaproicacid, mecamylamine hydrochloride, procainamide hydrochloride,amphetamine sulfate, methamphetamine hydrochloride, benzphetaminehydrochloride, isoproterenol sulfate, phenmetrazine hydrochloride,bethanechol chloride, methacholine chloride, pilocarpine hydrochloride,atropine sulfate, scopolamine bromide, isopropamide iodide,tridihexethyl chloride, phenformin hydrochloride, methylphenidatehydrochloride, theophylline cholinate, cephalexin hydrochloride,diphenidol, meclizine hydrochloride, prochlorperazine maleate,phenoxybenzamine, thiethylperazine maleate, anisindione, diphenadioneerythrityl tetranitrate, digoxin, isoflurophate, acetazolamide,nifedipine, methazolamide, bendroflumethiazide, chlorpropamide,glipizide, glyburide, gliclazide, tobutamide, chlorproamide, tolazamide,acetohexamide, metformin, troglitazone, orlistat, bupropion, nefazodone,tolazamide, chlormadinone acetate, phenaglycodol, allopurinol, aluminumaspirin, methotrexate, acetyl sulfisoxazole, hydrocortisone,hydrocorticosterone acetate, cortisone acetate, dexamethasone and itsderivatives such as betamethasone, triamcinolone, methyltestosterone,17-β-estradiol, ethinyl estradiol, ethinyl estradiol 3-methyl ether,prednisolone, 17-β-hydroxyprogesterone acetate, 19-nor-progesterone,norgestrel, norethindrone, norethisterone, norethiederone, progesterone,norgesterone, norethynodrel, terfandine, fexofenadine, aspirin,acetaminophen, indomethacin, naproxen, fenoprofen, sulindac, indoprofen,nitroglycerin, isosorbide dinitrate, propranolol, timolol, atenolol,alprenolol, cimetidine, clonidine, imipramine, levodopa, selegiline,chlorpromazine, methyldopa, dihydroxyphenylalanine, calcium gluconate,ketoprofen, ibuprofen, cephalexin, erythromycin, haloperidol, zomepirac,ferrous lactate, vincamine, phenoxybenzamine, diltiazem, mirinone,captropril, mandol, quanbenz, hydrochlorothiazide, ranitidine,flurbiprofen, fenbufen, fluprofen, tolmetin, alclofenac, mefenamic,flufenamic, difuninal, nimodipine, nitrendipine, nisoldipine,nicardipine, felodipine, lidoflazine, tiapamil, gallopamil, amlodipine,mioflazine, lisinopril, enalapril, captopril, ramipril, enalaprilat,famotidine, nizatidine, sucralfate, etintidine, tetratolol, minoxidil,chlordiazepoxide, diazepam, amitriptyline, and imipramine, andpharmaceutical salts of these active agents. Further examples areproteins and peptides which include, but are not limited to, insulin,colchicine, glucagon, thyroid stimulating hormone, parathyroid andpituitary hormones, calcitonin, renin, prolactin, corticotrophin,thyrotropic hormone, follicle stimulating hormone, chorionicgonadotropin, gonadotropin releasing hormone, bovine somatotropin,porcine somatropin, oxytocin, vasopressin, prolactin, somatostatin,lypressin, pancreozymin, luteinizing hormone, LHRH, interferons,interleukins, growth hormones such as human growth hormone, bovinegrowth hormone and porcine growth hormone, fertility inhibitors such asthe prostaglandins, fertility promoters, growth factors, and humanpancreas hormone releasing factor.

The present invention has particular utility in the delivery of liquid,active agent formulations that are in the form of emulsions orself-emulsifying compositions. The term emulsion as used in thisspecification denotes a two-phase system in which one phase is finelydispersed in the other phase. The term emulsifier, as used by thisinvention, denotes an agent that can reduce and/or eliminate the surfaceand the interfacial tension in a two-phase system. The emulsifier agent,as used herein, denotes an agent possessing both hydrophilic andlipophilic groups in the emulsifier agent. The term microemulsion, asused herein, denotes a multicomponent system that exhibits a homogenoussingle phase in which quantities of a drug can be solubilized.Typically, a microemulsion can be recognized and distinguished fromordinary emulsions in that the microemulsion is more stable and usuallysubstantially transparent. The term solution, as used herein, indicatesa chemically and physically homogenous mixture of two or moresubstances.

The emulsion formulations of active agent generally comprise 0.5 wt % to99 wt % of a surfactant. The surfactant functions to preventaggregation, reduce interfacial tension between constituents, enhancethe free-flow of constituents, and lessen the incidence of constituentretention in the dosage form. The therapeutic emulsion formulationsuseful in this invention may comprise a surfactant that impartsemulsification comprising a member selected from the group consisting ofpolyoxyethylenated castor oil comprising 9 moles of ethylene oxide,polyoxyethylenated castor oil comprising 15 moles of ethylene oxide,polyoxyethylene castor oil comprising 20 moles of ethylene oxide,polyoxyethylenated castor oil comprising 25 moles of ethylene oxide,polyoxyethylenated castor oil comprising 40 moles of ethylene oxide,polyoxylenated castor oil comprising 52 moles of ethylene oxide,polyoxyethylenated sorbitan monopalmitate comprising 20 moles ofethylene oxide, polyoxyethylenated sorbitan monolaurate comprising 20moles of ethylene oxide, polyoxyethylenated sorbitan monooleatecomprising 20 moles of ethylene oxide, polyoxyethylenated sorbitanmonostearate comprising 20 moles of ethylene oxide, polyoxyethylenatedsorbitan monostearate comprising 4 moles of ethylene oxide,polyoxyethylenated sorbitan tristearate comprising 20 moles of ethyleneoxide, polyoxyethylenated sorbitan monostearate comprising 20 moles ofethylene oxide, polyoxyethylenated sorbitan trioleate comprising 20moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8moles of ethylene oxide, polyoxyethylene lauryl ether,polyoxyethylenated stearic acid comprising 40 moles of ethylene oxide,polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide,polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide,and polyoxyethylenated oleyl alcohol comprising 2 moles of ethyleneoxide. The surfactants are available from Atlas Chemical Industries,Wilmington, Del.; Drew Chemical Corp., Boonton, N.J.; and GAF Corp., NewYork, N.Y.

Typically, an active agent emulsified formulation useful in theinvention initially comprises an oil phase. The oil phase of theemulsion comprises any pharmaceutically acceptable oil which is notmiscible with water. The oil can be an edible liquid such as a non-polarester of an unsaturated fatty acid, derivatives of such esters, ormixtures of such esters can be utilized for this purpose. The oil can bevegetable, mineral, animal or marine in origin. Examples of non-toxicoils comprise a member selected from the group consisting of peanut oil,cottonseed oil, sesame oil, olive oil, corn oil, almond oil, mineraloil, castor oil, coconut oil, palm oil, cocoa butter, safflower, amixture of mono- and di- glycerides of 16 to 18 carbon atoms,unsaturated fatty acids, fractionated triglycerides derived from coconutoil, fractionated liquid triglycerides derived from short chain 10 to 15carbon atoms fatty acids, acetylated monoglycerides, acetylateddiglycerides, acetylated triglycerides, olein known also as glyceraltrioleate, palmitin known as glyceryl tripalmitate, stearin known alsoas glyceryl tristearate, lauric acid hexylester, oleic acid oleylester,glycolyzed ethoxylated glycerides of natural oils, branched fatty acidswith 13 molecules of ethyleneoxide, and oleic acid decylester. Theconcentration of oil, or oil derivative in the emulsion formulation is 1wt % to 40 wt %, with the wt % of all constituents in the emulsionpreparation equal to 100 wt %. The oils are disclosed in PharmaceuticalSciences by Remington, 17th Ed., pp. 403-405, (1985) published by MarkPublishing Co., in Encyclopedia of Chemistry, by Van Nostrand Reinhold,4^(th) Ed., pp. 644-645, (1986) published by Van Nostrand Reinhold Co.;and in U.S. Pat. No. 4,259,323 issued to Ranucci.

The dosage form and method of this invention may be applied generally toliquid formulations of active agents, which may be preparedconventionally as described herein and, for example, to those liquidformulations contained in commercially-available dosage forms. Examplesof commercially available encapsulated liquid formulations that may beutilized include, inter alia, Placidyl® brand of ethchlorvynol, Adalat®brand of nifedipine, VePesid® brand of etoposide, Lanoxicaps® brand ofdigoxin, Zantac® brand of ranitidine hydrochloride, Sandimmune® andNeoral® brands of cyclosporin, Calderol® brand of calcifediol, Zarontin®brand of ethosuximide, Procardia® brand of nifedipine, Rocaltrol® brandof calcitriol and Vescenoid® brand of tretinoin.

The dosage form may contain an antioxidant to slow or effectively stopthe rate of any autoxidizable material present in the dosage form,particularly if it is in the form of a gelatin capsule. Representativeantioxidants comprise a member selected from the group of ascorbic acid;alpha tocopherol; ascorbyl palmitate; ascorbates; isoascorbates;butylated hydroxyanisole; butylated hydroxytoluene; nordihydroguiareticacid; esters of garlic acid comprising at least 3 carbon atomscomprising a member selected from the group consisting of propylgallate, octyl gallate, decyl gallate , decyl gallate;6-ethoxy-2,2,4-trimethyl-1,2-dihydro-guinoline;N-acetyl-2,6-di-t-butyl-p-aminophenol; butyl tyrosine;3-tertiarybutyl-4-hydroxyanisole; 2-tertiary-butyl-4-hydroxyanisole;4-chloro-2,6-ditertiary butyl phenol; 2,6-ditertiary butyl p-methoxyphenol; 2,6-ditertiary butyl-p-cresol: polymeric antioxidants;trihydroxybutyro-phenone physiologically acceptable salts of ascorbicacid, erythorbic acid, and ascorbyl acetate; calcium ascorbate; sodiumascorbate; sodium bisulfite; and the like. The amount of antioxidantused for the present purposes is about 0.001% to 25% of the total weightof the composition present in the dosage form. Antioxidants are known tothe prior art in U.S. Pat. Nos. 2,707,154; 3,573,936; 3,637,772;4,038,434; 4,186,465 and 4,559,237.

The dosage form may also contain a chelating agent to protect the activeagent either during storage or when in use. Examples of chelating agentsinclude, for example, polyacrylic acid, citric acid, edetic acid,disodium edetic acid, and the like. The chelating agent may beco-delivered with the active agent in the environment of use to preserveand protect the active agent in situ. Protection is provided for activeagents which are inactivated by chelation with multivalent metal cationssuch as calcium, magnesium or aluminum that may be present in some foodsand are at natural background levels in the fluids of thegastrointestinal tract. Such chelating agents may be combined with theliquid, active agent formulation in the porous particles, or thechelating agents may be incorporated into the drug layer in which theporous particles are dispersed.

The liquid formulation may also comprise a surfactant or a mixture ofsurfactants where the surfactant is selected from the group consistingof nonionic, anionic and cationic surfactants. Exemplary nontoxic,nonionic surfactants suitable for forming a composition comprisealkylated aryl polyether alcohols known as Triton®; polyethylene glycoltertdodecyl throether available as Nonic®; fatty and amide condensate orAlrosol®; aromatic polyglycol ether condensate or Neutronyx®; fatty acidalkanolamine or Ninol® sorbitan monolaurate or Span®; polyoxyethylenesorbitan esters or Tweens®; sorbitan monolaurate polyoxyethylene orTween 20®; sorbitan mono-oleate polyoxyethylene or Tween 80®;polyoxypropylene-polyoxyethylene or Pluronic®; polyglycolyzed glyceridessuch as Labraosol, polyoxyethylated castor oil such as Cremophor andpolyoxypropylene-polyoxyethylene-8500 or Pluronic®. By way of example,anionic surfactants comprise sulfonic acids and the salts of sulfonatedesters such as sodium lauryl sulfate, sodium sulfoethyl oleate, dioctylsodium sulfosuccinate, cetyl sulfate sodium, myristyl sulfate sodium;sulated esters; sulfated amides; sulfated alcohols; sulfated ethers;sulfated carboxylic acids; sulfonated aromatic hydrocarbons; sulfonatedethers; and the like. The cationic surface active agents comprise cetylpyridinium chloride; cetyl trimethyl ammonium bromide; diethylmethylcetyl ammonium chloride; benzalkonium chloride; benzethonium chloride;primary alkylamonium salts; secondary alkylamonium salts; tertiaryalkylamonium salts; quaternary alkylamonium salts; acylated polyamines;salts of heterocyclic amines; palmitoyl carnitine chloride,behentriamonium methosulfate, and the like. Generally, from 0.01 part to1000 parts by weight of surfactant, per 100 parts of active agent isadmixed with the active agent to provide the active agent formulation.Surfactants are known to the prior art in U.S. Pat. Nos. 2,805,977; andin 4,182,330.

The liquid formulation may comprise permeation enhancers that facilitateabsorption of the active agent in the environment of use. Such enhancersmay, for example, open the so-called “tight junctions” in thegastrointestinal tract or modify the effect of cellular components, sucha p-glycoprotein and the like. Suitable enhancers include alkali metalsalts of salicyclic acid, such as sodium salicylate, caprylic or capricacid, such as sodium caprylate or sodium caprate, and the like.Enhancers may include the bile salts, such as sodium deoxycholate.Various p-glycoprotein modulators are described in U.S. Pat. No.5,112,817 and 5,643,909, which are incorporated herein by reference.Various other absorption enhancing compounds and materials are describedin U.S. Pat. No. 5,824,638, which also is incorporated herein byreference. Enhancers may be used either alone or as mixtures incombination with other enhancers.

The liquid, active agent formulation of the dosage form may optionallybe formulated with inorganic or organic acids or salts of drugs whichpromote dissolution and disintegration or swelling of the porousparticles upon contact with biological fluids. The acids serve to lowerthe pH of the microenvironment at the porous particle, and promote rapiddissolution of a particle, such as calcium hydrogen phosphate, that issoluble in low pH environments, thus providing rapid liberation of theliquid, active agent formulation contained in the porous particle.Examples of organic acids include citric acid, tartaric acid, succinicacid, malic acid, fumaric acid and the like. Salts of drugs where theanion of the salt is acidic, such as acetate, hydrochloride,hydrobromide, sulfate, succinate, citrate, and the like, can be utilizedto produce immediate disintegration and dissolution of the porousparticle. A more complete list of acidic components for this applicationis provided in Journal of Pharmaceutical Sciences, “PharmaceuticalSalts”, Review Articles, January, (1977), Vol. 66, No. 1, pages 1-19.The interaction of an acidic component with a porous particle of, forexample, calcium hydrogen phosphate, in the presence of water fromgastric fluids accelerates dissolution of the particle at a greater ratethan gastric fluid alone, producing a more rapid and complete release ofthe liquid, active agent formulation into the environment of use.Likewise alkaline components or salts of drugs where the cation of thesalt is alkaline such as choline may be incorporated into the liquid,active agent formulation to promote rapid and complete dissolution of aporous particle which is soluble or swells at elevated pH. Such aparticle may be formed, for example, of poly(methacrylic acid-methylmethacrylate) 1:2 available commercially as Eudragit S100 (Rohm America,Sommerset, N.J.).

With reference to FIG. 1, a porous particle 10 is illustrated having amaterial mass 12 that defines a plurality of pores 14. Within the pores14 is sorbed a liquid, active agent formulation designated as 16. Pores14 extend from the external surface of the particle and into theinterior. Pores are open on the surface to permit the liquid, activeagent formulation to be sorbed into the particles by conventional mixingtechniques such as wet granulation, spraying of the liquid, active agentformulation onto a fluidized bed of the particles, or the like.

In FIG. 2, a composition is illustrated which contains the porousparticles 10 dispersed within a carrier 18. Typically, the compositionis compacted as a tablet to form the drug layer portion of the dosageform. During the compacting phase of the manufacture, it is desired thatthe particle mass 12 be sufficiently non-friable so as to resistpulverization or crushing and undesired exudation of the liquid, activeagent formulation.

A dosage form 20 intended for continuous, zero order release of theactive agent is illustrated in FIG. 3. As can be seen therein, thedosage form 20 comprises a wall 22 defining a cavity 24. Wall 22 isprovided with an exit orifice 26. Within cavity 24 and remote from theexit orifice 26 is a push layer 28. A drug layer 30 is located withincavity 24 adjacent exit orifice 26. A plurality of porous particles 10is dispersed in carrier 18 within the cavity 24 to form the drug layer30. An optional, flow-promoting layer 32, the function of which will bedescribed and which may be formed as a secondary wall, extends betweendrug layer 30 and the inner surface of wall 22. An orifice 26 isprovided at one end of dosage form 20 to permit expression of the druglayer 30 from the dosage form upon expansion of push layer 28.

The wall 22 is formed to be permeable to the passage of an externalfluid, such as water and biological fluids, and it is substantiallyimpermeable to the passage of active agent, osmagent, osmopolymer andthe like. As such, it is semipermeable. The selectively semipermeablecompositions used for forming the wall are essentially nonerodible andthey are insoluble in biological fluids during the life of the dosageform. Wall 22 need not be semipermeable in its entirety, but at least aportion of wall 22 should be semipermeable to allow fluid to contact orcommunicate with push layer 28 such that push layer 28 imbibes fluidduring use. Specific materials for the fabrication of semipermeable wall22 are well known in the art, and representative examples of suchmaterials are described later herein.

Secondary wall 32, which functions as the flow-promoting layer orlubricant, is in contacting position with the inner surface of thesemipermeable wall 22 and at least the external surface of the druglayer that is opposite wall 22; although the secondary wall 32 may, andpreferably will, extend to, surround and contact the external surface ofthe push layer. Wall 32 typically will surround at least that portion ofthe external surface of the drug layer that is opposite the internalsurface of wall 22. Secondary wall 32 may be formed as a coating appliedover the compressed core comprising the drug layer and the push layer.The outer semipermeable wall 22 surrounds and encases the inner,secondary wall 32. Secondary wall 32 is preferably formed as a subcoatof at least the surface of the drug layer 30, and optionally the entireexternal surface of the compacted drug layer 30 and the push layer 28.When the semipermeable wall 22 is formed as a coat of the compositeformed from the drug layer 30, the push layer 28 and the secondary wall32, contact of the semipermeable wall 22 with the inner coat is assured.

FIG. 4 illustrates another form of the invention wherein the dosage form20 includes a placebo layer 38 which serves to delay release ofparticles 10 in the environment of use. The other components of thedosage form 20 are substantially the same as those described withreference to FIG. 3, and like components are designated with the samereference numerals. The extent of the delay that may be afforded by theplacebo layer will in part depend on the volume of the placebo layer 38which has to be displaced by the push layer 28 as it imbibes fluid andexpands. FIGS. 6-10 illustrate different periods of delay that may beobtained by varying the placebo layer 38 when delivering arepresentative compound progesterone. The dosage forms for which theresults in FIGS. 6-10 are illustrated correspond to those described inExamples 4-8, respectively. Delays of 2 hours to 10 hours areillustrated.

Representative polymers for forming wall 22 comprise semipermeablehomopolymers, semipermeable copolymers, and the like. Such materialscomprise cellulose esters, cellulose ethers and cellulose ester-ethers.The cellulosic polymers have a degree of substitution (DS) of theiranhydroglucose unit of from greater than 0 up to 3, inclusive. Degree ofsubstitution (DS) means the average number of hydroxyl groups originallypresent on the anhydroglucose unit that are replaced by a substitutinggroup or converted into another group. The anhydroglucose unit can bepartially or completely substituted with groups such as acyl, alkanoyl,alkenoyl, aroyl, alkyl, alkoxy, halogen, carboalkyl, alkylcarbamate,alkylcarbonate, alkylsulfonate, alkysulfamate, semipermeable polymerforming groups, and the like, wherein the organic moieties contain fromone to twelve carbon atoms, and preferably from one to eight carbonatoms.

The semipermeable compositions typically include a member selected fromthe group consisting of cellulose acylate, cellulose diacylate,cellulose triacylate, cellulose acetate, cellulose diacetate, cellulosetriacetate, mono-, di- and tri-cellulose alkanylates, mono-, di-, andtri-alkenylates, mono-, di-, and tri-aroylates, and the like. Exemplarypolymers include cellulose acetate having a DS of 1.8 to 2.3 and anacetyl content of 32 to 39.9%; cellulose diacetate having a DS of 1 to 2and an acetyl content of 21 to 35%; cellulose triacetate having a DS of2 to 3 and an acetyl content of 34 to 44.8%; and the like. More specificcellulosic polymers include cellulose propionate having a DS of 1.8 anda propionyl content of 38.5%; cellulose acetate propionate having anacetyl content of 1.5 to 7% and an acetyl content of 39 to 42%;cellulose acetate propionate having an acetyl content of 2.5 to 3%, anaverage propionyl content of 39.2 to 45%, and a hydroxyl content of 2.8to 5.4%; cellulose acetate butyrate having a DS of 1.8, an acetylcontent of 13 to 15%, and a butyryl content of 34 to 39%; celluloseacetate butyrate having an acetyl content of 2 to 29%, a butyryl contentof 17 to 53%, and a hydroxyl content of 0.5 to 4.7%; cellulosetriacylates having a DS of 2.6 to 3, such as cellulose trivalerate,cellulose trilamate, cellulose tripalmitate, cellulose trioctanoate andcellulose tripropionate; cellulose diesters having a DS of 2.2 to 2.6,such as cellulose disuccinate, cellulose dipalmitate, cellulosedioctanoate, cellulose dicaprylate, and the like; and mixed celluloseesters, such as cellulose acetate valerate, cellulose acetate succinate,cellulose propionate succinate, cellulose acetate octanoate, cellulosevalerate palmitate, cellulose acetate heptanoate, and the like.Semipermeable polymers are known in U.S. Pat. No. 4,077,407, and theycan be synthesized by procedures described in Encyclopedia of PolymerScience and Technology, Vol. 3, pp. 325-354 (1964), lntersciencePublishers Inc., New York, N.Y.

Additional semipermeable polymers for forming the outer wall 22 comprisecellulose acetaldehyde dimethyl acetate; cellulose acetateethylcarbamate; cellulose acetate methyl carbamate; cellulosedimethylaminoacetate; semipermeable polyamide; semipermeablepolyurethanes; semipermeable sulfonated polystyrenes; cross-linkedselectively semipermeable polymers formed by the coprecipitation of ananion and a cation, as disclosed in U.S. Pat. Nos. 3,173,876; 3,276,586;3,541,005; 3,541,006 and 3,546,142; semipermeable polymers, as disclosedby Loeb, et al. in U.S. Pat. No. 3,133,132; semipermeable polystyrenederivatives; semipermeable poly(sodium styrenesulfonate); semipermeablepoly(vinylbenzyltrimethylammonium chloride); and semipermeable polymersexhibiting a fluid permeability of 10⁻⁵ to 10⁻² (cm. mil/atm. hr),expressed as per atmosphere of hydrostatic or osmotic pressuredifferences across a semipermeable wall. The polymers are known to theart in U.S. Pat. Nos. 3,845,770; 3,916,899 and 4,160,020; and inHandbook of Common Polymers, Scott and Roff (1971) CRC Press, Cleveland,Ohio

Wall 22 also can comprise a flux regulating agent. The flux regulatingagent is a compound added to assist in regulating the fluid permeabilityor flux through wall 22. The flux regulating agent can be a fluxenhancing agent or a decreasing agent. The agent can be preselected toincrease or decrease the liquid flux. Agents that produce a markedincrease in permeability to fluid such as water, are often essentiallyhydrophilic, while those that produce a marked decrease to fluids suchas water, are essentially hydrophobic. The amount of regulator in thewall when incorporated therein generally is from about 0.01% to 20% byweight or more. The flux regulator agents in one embodiment thatincrease flux include polyhydric alcohols, polyalkylene glycols,poilyalkylenediols, polyesters of alkylene glycols, and the like.Typical flux enhancers include polyethylene glycol 300, 400, 600, 1500,4000, 6000 and the like; low molecular weight gylcols such aspolypropylene glycol, polybutylene glycol and polyamylene glycol: thepolyalkylenediols such as poly(1,3-propanediol), poly(1,4-butanediol),poly(1,6-hexanediol), and the like; aliphatic diols such as 1,3-butyleneglycol, 1,4-pentamethylene glycol, 1,4-hexamethylene glycol, and thelike; alkylene triols such as glycerine, 1,2,3-butanetriol,1,2,4-hexanetriol, 1,3,6-hexanetriol and the like; esters such asethylene glycol dipropionate, ethylene glycol butyrate, butylene glycoldipropionate, glycerol acetate esters, and the like. Representative fluxdecreasing agents include phthalates substituted with an alkyl or alkoxyor with both an alkyl and alkoxy group such as diethyl phthalate,dimethoxyethyl phthalate, dimethyl phthalate, and [di(2-ethylhexyl)phthalate], aryl phthalates such as triphenyl phthalate, and butylbenzyl phthalate; insoluble salts such as calcium sulphate, bariumsulphate, calcium phosphate, and the like; insoluble oxides such astitanium oxide; polymers in powder, granule and like form such aspolystyrene, polymethylmethacrylate, polycarbonate, and polysulfone;esters such as citric acid esters esterfied with long chain alkylgroups; inert and substantially water impermeable fillers; resinscompatible with cellulose based wall forming materials, and the like.

Other materials that can be used to form the wall 22 for impartingflexibility and elongation properties to the wall, for making wall 22less-to-nonbrittle and to render tear strength, include phthalateplasticizers such as dibenzyl phthalate, dihexyl phthalate, butyl octylphthalate, straight chain phthalates of six to eleven carbons,di-isononyl phthalte, di-isodecyl phthalate, and the like. Theplasticizers include nonphthalates such as triacetin, dioctyl azelate,epoxidized tallate, tri-isoctyl trimellitate, tri-isononyl trimellitate,sucrose acetate isobutyrate, epoxidized soybean oil, and the like. Theamount of plasticizer in a wall when incorporated therein is about 0.01%to 20% weight, or higher.

The drug layer 30 may comprise a composition formed of a liquid activeagent formulation absorbed in porous particles, the preferredcharacteristics of the particles being described elsewhere herein, and acarrier 18. Depending on the release characteristics desired, thecarrier may be a binder, which may be a hydrophilic polymer. Thehydrophilic polymer provides a hydrophilic polymer composition in thedrug layer that may contribute to the uniform release rate of activeagent and controlled delivery pattern by controlling the rate of releaseof the porous particles containing the liquid, active agent formulationfrom the dosage form over a sustained period of time. Representativeexamples of these polymers are poly(alkylene oxide) of 100,000 to750,000 number-average molecular weight, including poly(ethylene oxide),poly(methylene oxide), poly(butylene oxide) and poly(hexylene oxide);and a poly(carboxymethylcellulose) of 40,000 to 400,000 number-averagemolecular weight, represented by poly(alkali carboxymethylcellulose),poly(sodium carboxymethylcellulose), poly(potassiumcarboxymethylcellulose) and poly(lithium carboxymethylcellulose). Thedrug composition can comprise a hydroxypropylalkylcellulose of 9,200 to125,000 number-average molecular weight for enhancing the deliveryproperties of the dosage form as represented byhydroxypropylethylcellulose, hydroxypropyl methylcellulose,hydroxypropylbutylcellulose and hydroxypropylpentylcellulose; and apoly(vinylpyrrolidone) of 7,000 to 360,000 number-average molecularweight for enhancing the flow properties of the dosage form. Preferredamong those polymers are the poly(ethylene oxide) of 100,000-300,000number average molecular weight. Carriers that erode in the gastricenvironment, i.e., bioerodible carriers, are especially preferred.

Surfactants and disintegrants may be utilized in the carrier as well.Exemplary of the surfactants are those having an HLB value of betweenabout 10-25, such as polyethylene glycol 400 monostearate,polyoxyethylene-4-sorbitan monolaurate, polyoxyethylene-20-sorbitanmonooleate, polyoxyethylene-20-sorbitan monopalmitate,polyoxyethylene-20-monolaurate, polyoxyethylene-40-stearate, sodiumoleate and the like. Disintegrants may be selected from starches, clays,celluloses, algins and gums and crosslinked starches, celluloses andpolymers. Representative disintegrants include corn starch, potatostarch, croscarmelose, crospovidone, sodium starch glycolate, Veegum HV,methylcellulose, agar, bentonite, carboxymethylcellulose, alginic acid,guar gum and the like.

In those cases where rapid release of drug is desired, the carrier inthe drug layer may be eliminated or present in only small amounts, andmay comprise a binder and/or disintegrant. Representative formulationsof such dosage forms are described in more detail in Examples 7 and 8for the materials calcium hydrogen phosphate and magnesiumaluminometasilicate.

The drug layer 30 may be formed as a mixture containing the porousparticles and the carrier. The carrier portion of the drug layer may beformed from particles by comminution that produces the desired size ofthe carrier particle used in the fabrication of the drug layer. Themeans for producing carrier particles include granulation, spray drying,sieving, lyophilization, crushing, grinding, jet milling, micronizingand chopping to produce the intended micron particle size. The processcan be performed by size reduction equipment, such as a micropulverizermill, a fluid energy grinding mill, a grinding mill, a roller mill, ahammer mill, an attrition mill, a chaser mill, a ball mill, a vibratingball mill, an impact pulverizer mill, a centrifugal pulverizer, a coarsecrusher and a fine crusher. The size of the particle can be ascertainedby screening, including a grizzly screen, a flat screen, a vibratingscreen, a revolving screen, a shaking screen, an oscillating screen anda reciprocating screen. The processes and equipment for preparing drugand carrier particles are disclosed in Pharmaceutical Sciences,Remington, 17th Ed., pp.1585-1594 (1985); Chemical Engineers Handbook,Perry, 6th Ed., pp. 21-13 to 21-19 (1984); Journal of PharmaceuticalSciences, Parrot, Vol. 61, No. 6, pp. 813-829 (1974); and ChemicalEngineer, Hixon, pp. 94-103 (1990).

The active compound may be provided in the liquid active agentformulation in amounts of from 1 microgram to 5000 mg per dosage form,depending upon the required dosing level that must be maintained overthe delivery period, i.e., the time between consecutive administrationsof the dosage forms. More typically, loading of compound in the dosageforms will provide doses of compound to the subject ranging from 1microgram to 2500 mg per day, more usually 1 mg to 2500 mg per day. Thedrug layer typically will be a substantially dry composition formed bycompression of the carrier and the porous particles, with theunderstanding that the porous particles will have contained therein theliquid, active agent formulation. The push layer will push the druglayer from the exit orifice as the push layer imbibes fluid from theenvironment of use, and the exposed drug layer will be eroded to releasethe porous particles into the environment of use. This may be seen withreference to FIG. 3.

The push layer 28 is an expandable layer having a push-displacementcomposition in direct or indirect contacting layered arrangement withthe drug layer 30. When in indirect contacting layered arrangement, aninert element (not shown), such as a spacer layer or disk, may be placedbetween the drug layer and the push layer. If several pulses of activeagent are to be delivered from a single dosage form, similar inertlayers may be interposed between discrete portions of drug layer. Theinert layer(s) may be sized to provide appropriate time delay(s) betweenpulses of active agent and the volume of each discrete drug layer willprovide control of the time period over which the pulse of active agentis delivered. Inert layers may be formed of materials utilized to formthe push layer 28, or if desired, formed of materials that are easilycompacted but do not swell in the fluid environment of use.

Push layer 28 comprises a polymer that imbibes an aqueous or biologicalfluid and swells to push the drug composition through the exit means ofthe device. Representatives of fluid-imbibing displacement polymerscomprise members selected from poly(alkylene oxide) of 1 million to 15million number-average molecular weight, as represented by poly(ethyleneoxide) and poly(alkali carboxymethylcellulose) of 500,000 to 3,500,000number-average molecular weight, wherein the alkali is sodium, potassiumor lithium. Examples of additional polymers for the formulation of thepush-displacement composition comprise osmopolymers comprising polymersthat form hydrogels, such as Carbopol® acidic carboxypolymer, a polymerof acrylic cross-linked with a polyallyl sucrose, also known ascarboxypolymethylene, and carboxyvinyl polymer having a molecular weightof 250,000 to 4,000,000; Cyanamer® polyacrylamides; cross-linked waterswellable indenemaleic anhydride polymers; Good-rite® polyacrylic acidhaving a molecular weight of 80,000 to 200,000; Aqua-Keeps® acrylatepolymer polysaccharides composed of condensed glucose units, such asdiester cross-linked polygluran; and the like. Representative polymersthat form hydrogels are known to the prior art in U.S. Pat. No.3,865,108, issued to Hartop; U.S. Pat. No. 4,002,173, issued to Manning;U.S. Pat. No. 4,207,893, issued to Michaels; and in Handbook of CommonPolymers, Scott and Roff, Chemical Rubber Co., Cleveland, Ohio.

The osmagent, also known as osmotic solute and osmotically effectiveagent, which exhibits an osmotic pressure gradient across the outer walland subcoat, comprises a member selected from the group consisting ofsodium chloride, potassium chloride, lithium chloride, magnesiumsulfate, magnesium chloride, potassium sulfate, sodium sulfate, lithiumsulfate, potassium acid phosphate, mannitol, urea, inositol, magnesiumsuccinate, tartaric acid raffinose, sucrose, glucose, lactose, sorbitol,inorganic salts, organic salts and carbohydrates.

Use of the inner wall or subcoat 32 is optional, but presentlypreferred. The inner subcoat 32 typically may be 0.01 to 5 mm thick,more typically 0.025-0.25 mm thick, although a thicker subcoat, forexample 0.5 to 5 mm thick, may be used in certain applications. Theinner subcoat 32 comprises a member selected from hydrogels, gelatin,low molecular weight polyethylene oxides, e.g., less than 100,000 MW,hydroxyalkylcelluloses, e.g., hydroxyethylcellulose,hydroxypropylcellulose, hydroxyisopropylcelluose, hydroxybutylcelluloseand hydroxyphenylcellulose, and hydroxyalkyl alkylcelluloses, e.g.,hydroxypropyl methylcellulose, and mixtures thereof. Thehydroxyalkylcelluloses comprises polymers having a 9,500 to 1,250,000number-average molecular weight. For example, hydroxypropyl celluloseshaving number average molecular weights of between 80,000 to 850,000 areuseful. The flow promoting layer may be prepared from conventionalsolutions or suspensions of the aforementioned materials in aqueoussolvents or inert organic solvents. Prefered materials for the subcoator flow promoting layer include hydroxypropyl cellulose, hydroxyethylcellulose, hydroxypropyl methyl cellulose, povidone[poly(vinylpyrrolidone)], polyethylene glycol, and mixtures thereof.More prefered are mixtures of hydroxypropyl cellulose and povidone,prepared in organic solvents, particularly organic polar solvents suchas lower alkanols having 1-8 carbon atoms, preferably ethanol, mixturesof hydroxyethyl cellolose and hydroxypropyl methyl cellulose prepared inaqueous solution, and mixtures of hydroxyetyyl cellulose andpolyethylene glycol prepared in aqueous solution. Most preferably, thesubcoat consists of a mixture of hydroxypropyl cellulose and povidoneprepared in ethanol. Conveniently, the weight of the subcoat applied tothe bilayer core may be correlated with the thickness of the subcoat andresidual drug remaining in a dosage form in a release rate assay such asdescribed herein. During manufacturing operations, the thickness of thesubcoat may be controlled by controlling the weight of the subcoat takenup in the coating operation. When wall 32 is fabricated of a gel-formingmaterial, contact with water in the environment of use facilitatesformation of a gel or gel-like inner coat having a viscosity that maypromote and enhance slippage between outer wall 22 and drug layer 30.

Exemplary solvents suitable for manufacturing the respective walls,layers, coatings and subcoatings utilized in the dosage forms of theinvention comprise aqueous and inert organic solvents that do notadversely harm the materials utilized to fabricate the dosage forms. Thesolvents broadly include members selected from the group consisting ofaqueous solvents, alcohols, ketones, esters, ethers, aliphatichydrocarbons, halogenated solvents, cycloaliphatics, aromatics,heterocyclic solvents and mixtures thereof. Typical solvents includeacetone, diacetone alcohol, methanol, ethanol, isopropyl alcohol, butylalcohol, methyl acetate, ethyl acetate, isopropyl acetate, n-butylacetate, methyl isobutyl ketone, methyl propyl ketone, n-hexane,n-heptane, ethylene glycol monoethyl ether, ethylene glycol monoethylacetate, methylene dichloride, ethylene dichloride, propylenedichloride, carbon tetrachloride nitroethane, nitropropanetetrachloroethane, ethyl ether, isopropyl ether, cyclohexane,cyclooctane, benzene, toluene, naphtha, 1,4-dioxane, tetrahydrofuran,diglyme, water, aqueous solvents containing inorganic salts such assodium chloride, calcium chloride, and the like, and mixtures thereofsuch as acetone and water, acetone and methanol, acetone and ethylalcohol, methylene dichloride and methanol, and ethylene dichloride andmethanol.

Pan coating may be conveniently used to provide the completed dosageform, except for the exit orifice. In the pan coating system, thesubcoat on the wall-forming compositions is deposited by successivespraying of the respective composition on the bilayered core comprisingthe drug layer and the push layer accompanied by tumbling in a rotatingpan. A pan coater is used because of its availability at commercialscale. Other techniques can be used for coating the drug core. Finally,the wall or coated dosage form are dried in a forced-air oven, or in atemperature and humidity controlled oven to free the dosage form ofsolvent. Drying conditions will be conventionally chosen on the basis ofavailable equipment, ambient conditions, solvents, coatings, coatingthickness,and the like.

Other coating techniques can also be employed. For example, thesemipermeable wall and the subcoat of the dosage form can be formed inone technique using the air-suspension procedure. This procedureconsists of suspending and tumbling the bilayer core in a current ofair, an inner subcoat composition and an outer semipermeable wallforming composition, until, in either operation, the subcoat and theouter wall coat is applied to the bilayer core. The air-suspensionprocedure is well suited for independently forming the wall of thedosage form. The air-suspension procedure is described in U.S. Pat. No.2,799,241; in J. Am. Pharm. Assoc., Vol. 48, pp. 451-459 (1959); and,ibid., Vol. 49, pp. 82-84 (1960). The dosage form also can be coatedwith a Wurster® air-suspension coater using, for example, methylenedichloride methanol as a cosolvent. An Aeromatic® air-suspension coatercan be used employing a cosolvent.

The dosage form of the invention may be manufactured by standardtechniques. For example, the dosage form may be manufactured by the wetgranulation technique. In the wet granulation technique a solution,suspension or dispersion of the active agent in a liquid is mixed withthe porous particles to allow the liquid, active agent formulation tosorb into the pores of the porous particles. Then the carrier is blendedwith the porous particles using an organic solvent, such as denaturedanhydrous ethanol, as the granulation fluid. After a wet blend isproduced, the wet mass blend is forced through a predetermined screenonto trays. The blend is dried under ambient conditions until thedesired moisture level is obtained. The drying conditions are not sosevere, however, that the liquid of the liquid, active agent formulationis allowed to evaporate to any significant extent. Next, a lubricantsuch as magnesium stearate or agglomerated silicon dioxide (Cab-O-Sil)for example, is added to the blend, which is then put into milling jarsand mixed on a jar mill for several minutes. The composition is pressedinto a layer, for example, in a Manesty® press. The first compressedlayer is typically the drug layer, and then the push layer may bepressed against the composition forming the drug layer, and the bilayertablets are fed to the Kilian® Dry Coater and surrounded with thedrug-free coat, followed by the exterior wall solvent coating. In thoseinstances where a trilayer dosage form for pulsatile release having aplacebo layer is to be fabicated, the placebo layer is usually formedfirst, then the drug layer is pressed onto the placebo layer to form abilayer composition, and then the push layer is compressed onto thebilayer core to form the trilayer composition. The trilayer tablet isthen provided with the option subcoat and the membrane coat for the ratecontrolling membrane. It is apparent, however, that the order in whichthe respective layers are compressed may be different, but the foregoingis preferred.

In another manufacture the porous particles containing the liquid,active agent formulation and other ingredients comprising the drug layerare blended and pressed into a solid layer. The layer possessesdimensions that correspond to the internal dimensions of the area thelayer is to occupy in the dosage form, and it also possesses dimensionscorresponding to the second layer for forming a contacting arrangementtherewith. The drug layer components can also be blended with a solventand mixed into a solid or semisolid form by conventional methods, suchas ballmilling, calendering, stirring or rollmilling, and then pressedinto a preselected shape. Next, the expandable layer, e.g., a layer ofosmopolymer composition, is placed in contact with the layer of drug ina like manner. The layering of the drug formulation and the osmopolymerlayer can be fabricated by conventional two-layer press techniques. Thetwo contacted layers are first coated with the flow-promoting subcoatand then an outer semipermeable wall. The air-suspension andair-tumbling procedures comprise in suspending and tumbling the pressed,contacting first and second layers in a current of air containing thedelayed-forming composition until the first and second layers aresurrounded by the wall composition.

The dosage form of the invention is provided with at least one exitorifice. The exit orifice cooperates with the drug core for the uniformrelease of drug from the dosage form. The exit orifice can be providedduring the manufacture of the dosage form or during drug delivery by thedosage form in a fluid environment of use. The expression “exit orifice”as used for the purpose of this invention includes a member selectedfrom the group consisting of a passageway; an aperture; an orifice; anda bore. The expression also includes an orifice that is formed from asubstance or polymer that erodes, dissolves or is leached from the outercoat or wall or inner coat to form an exit orifice. The substance orpolymer may include an erodible poly(glycolic) acid or poly(lactic) acidin the outer or inner coats; a gelatinous filament; a water-removablepoly(vinyl alcohol); a leachable compound, such as a fluid removablepore-former selected from the group consisting of inorganic and organicsalt, oxide and carbohydrate. An exit, or a plurality of exits, can beformed by leaching a member selected from the group consisting ofsorbitol, lactose, fructose, glucose, mannose, galactose, talose, sodiumchloride, potassium chloride, sodium citrate and mannitol to provide auniform-release dimensioned pore-exit orifice. The exit orifice can haveany shape, such as round, triangular, square, elliptical and the likefor the uniform metered dose release of a drug from the dosage form. Thedosage form can be constructed with one or more exits in spaced apartrelation or one or more surfaces of the dosage form. The exit orificecan be performed by drilling, including mechanical and laser drilling,through the outer coat, the inner coat, or both. Exits and equipment forforming exits are disclosed in U.S. Pat. Nos. 3,845,770 and 3,916,899,by Theeuwes and Higuchi; in U.S. Pat. No. 4,063,064, by Saunders, etal.; and in U.S. Pat. No. 4,088,864, by Theeuwes, et al. The exitorifice may be from 10% to 100% of the inner diameter of the compartmentformed by wall 22, preferably from 30% to 100%, and most preferably from50% to 100%.

The continuous release dosage forms provide a uniform rate of release ofcompound over a prolonged period of time, typically from about zerohours, the time of administration, to about 4 hours to 20 hours or more,often for 4 hours to 16 hours, and more usually for a time period of 4hours to 10 hours. At the end of a prolonged period of uniform release,the rate of release of drug from the dosage form may decline somewhatover a period of time, such as several hours. The dosage forms providetherapeutically effective amounts of drug for a broad range ofapplications and individual subject needs. The results of the release ofprogesterone from a representative, continuous release dosage form ofthis invention is provided in FIG. 5. As can be seen therefrom,progesterone is released over a period of time extending up to about 15hours. In FIG. 5, the filled circles represent a drug granulation thatdoes not contain any PVP (polyvinylpyrollidone), the empty trianglesrepresent a drug granulation containing 10% PVP, and the filled squaresand filled diamonds represent drug granulations containing 10% maltose.In each case, the dosage forms were formed as trilayer, continuoussystem with (1) a mannitol layer adjacent the exit orifice that quicklydissolves in the release bath, (2) a drug layer containing progesteronedispersed in Cremophor EUMyvacet in calcium hydrogen phosphate in aratio of 45/55% by weight as described in greater detail in Example 1,and (3) a push layer.

The dosage forms may also provide active agent in a pulsatile releaseprofile. With reference to FIGS. 6-10, varying delays in the onset ofthe release of active agent are illustrated with formulation preparedfrom calcium hydrogen phosphate particles. Those results are achievedwith the dosage forms described in Examples 2-6, respectively. Resultsfor representative formulations prepared from magnesiumaluminometasilicate particles as prepared in Examples 7 and 8 areillustrated in FIGS. 13 and 14. By varying the volume or weight of theplacebo layer and/or the weight of the semipermeable membrane, it ispossible to control the initial period before active agent is releasedfrom the dosage form. For pulse formulations, the drug layer may beformed as a rapid release layer in which the carrier in the drug layeris eliminated or is minimally present so as to allow for rapid releaseof the drug particles and the liquid, active agent formulation to theenvironment of use. The use of a disintegrant or other agent tofacilitate break-up of the porous particles may be utilized. Forsustained release formulations, the general considerations surroundingthe selection of parameters of the push layer, the placebo layer and thesemipermeable membrane to provide a desired period of delay prior toonset of delivery of the active agent will be similar as with the pulseformulation. However, as described herein, a carrier, such as abioerodible hydrophilic polymer or the like, may generally be utilizedin greater amount to provide for continuous release of the porousparticles and active agent over time.

With zero order release, upon initial administration, the dosage formsmay provide a drug concentration in the plasma of the subject thatincreases over an initial period of time, typically several hours orless, and then provide a relatively constant concentration of drug inthe plasma over a prolonged period of time, typically 4 hours to 24hours or more. The release profiles of the dosage forms of thisinvention provide release of drug over the entire 24-hour periodcorresponding to once-a-day administration, such that steady stateconcentration of drug in blood plasma of a subject may be maintained attherapeutically effective levels over a 24 hour period afteradministration the sustained release dosage form. Steady state plasmalevels of drug may typically be achieved after twenty-four hours or, insome cases, several days, e.g., 2-5 days, in most subjects.

Continuous or sustained release dosage forms of this invention releasedrug at a uniform rate of release over a prolonged period of time asdetermined in a standard release rate assay such as that describedherein. When administered to a subject, the dosage forms of theinvention provide blood plasma levels of drug in the subject that areless variable over a prolonged period of time than those obtained withimmediate release dosage forms. When the dosage forms of this inventionare administered on a regular, once-a-day basis, the dosage forms of theinvention provide steady state plasma levels of drug such that thedifference between C_(max) and C_(min) over the 24-hour period issubstantially reduced over that obtained from administration of animmediate release product that is intended to release the same amount ofdrug in the 24-hour period as is provided from the dosage forms of theinvention

The dosage forms of this invention may be adapted to release activeagent at a uniform rate of release rate over a prolonged period of time,preferably 4-6 hours or more. Measurements of release rate are typicallymade in vitro, in acidified water, simulated gastric fluid or simulatedintestinal fluid to provide a simulation of conditions in specificbiological locations, and are made over finite, incremental time periodsto provide an approximation of instantaneous release rate. Informationof such in vitro release rates with respect to a particular dosage formmay be used to assist in selection of dosage form that will providedesired in vivo results. Such results may be determined by presentmethods, such as blood plasma assays and clinical observation, utilizedby practitioners for prescribing available immediate release dosageforms.

Dosage forms of the present invention having zero order release rateprofiles as described herein may provide to a patient a substantiallyconstant blood plasma concentration and a sustained therapeutic effectof active agent, after administration of the dosage form, over aprolonged period of time. The sustained release dosage forms of thisinvention demonstrate less variability in drug plasma concentration overa 24-hour period than do immediate release formulations, whichcharacteristically create significant peaks in drug concentrationshortly or soon after administration to the subject.

The dosage forms of the invention may have a delayed onset of actionincorporated directly into the dosage form by means of the placebo layerthat has been described. For particular applications, it may bedesirable to deliver a plurality of the dosage forms, with or without aplacebo layer or other drug layer design, at a single location in thegastrointestinal tract. This may effected conveniently by combining thedosage forms of the invention with associated technology, such as forexample, the Chronset® drug delivery system of Alza Corporation, PaloAlto, Calif. Such systems can be programmed to release the dosage formsat designated times and at targeted absorption sites. That technology isdescribed in U.S. Pat. Nos. 5,110,597; 5,223,265; 5,312,390; 5,443,459;5,417,682; 5,498,255; 5,531,736; and 5,800,422, which are incorporatedherein by reference. The composite delivery system may be manufacturedby loading the osmotic dosage forms described herein into the Chronset®systems, and provide for the controlled release of active agent in avariety of formats. An illustrative general method of manufacturingdosage forms of the invention is described below in the PREPARATION.Percentages are percentages by weight unless noted otherwise. Variationsin the methods and substitution of materials may be made and will beapparent from the earlier description. Equivalent or proportionalamounts of such materials may be substituted for those used in thePREPARATION below. More specific descriptions are provided in theExamples and alternative materials and procedures are illustratedtherein.

PREPARATION

Preparation of the Drug Layer

A binder solution is prepared by adding hydroxypropyl cellulose (KlucelMF, Aqualon Company), “HPC”, to water to form a solution containing 5 mgof HPC per 0.995 grams of water. The solution is mixed until thehydroxypropyl cellulose is dissolved. For a particular batch size, afluid bed granulator (“FBG”) bowl is charged with the required amountsof liquid, active agent formulation and the corresponding amount ofporous particles, such as exemplified by the calcium hydrogen phosphateparticles sold under the trademark FujiCalin. After the liquid isabsorbed by the particles, the blend is mixed with, polyethylene oxide(MW 200,000) (Polyox® N-80, Union Carbide Corporation) (20.3%),hydroxypropyl cellulose (Klucel MF) (5%), polyoxyl 40 stearate (3%) andcrospovidone (2%). After mixing the semi-dry materials in the bowl, thebinder solution prepared as above is added. Then the granulation isdried in the FBG to a dough-like consistency suitable for milling, andthe granulation is milled through a 7 or a 10 mesh screen.

The granulation is transferred to a tote blender or a V-blender. Therequired amounts of antioxidant, butylated hydroxytoluene (“BHT”)(0.01%), and lubricant, stearic acid (1%), are sized through a 40 meshscreen and both are blended into the granulation using the tote orV-blender until uniformly dispersed (about 1 minute of blending forstearic acid and about 10 minutes of blending for BHT.

Preparation of the Osmotic Push Layer Granulation

A binder solution is prepared by adding hydroxypropyl methylcellulose2910 (“HPMC”) to water in a ratio of 5 mg of HPMC to 1 g of water. Thesolution is mixed until the HPMC is dissolved. Sodium chloride powder(30%) and red ferric oxide (1.0%) are milled and screened. A fluid bedgranulator (“FBG”) bowl is charged with the required amounts ofpolyethylene oxide (MW 7,000,000) (Polyox® 303) (63.7%), HPMC (5.0%),the sodium chloride and the red ferric oxide. After mixing the drymaterials in the bowl, the binder solution prepared above is added. Thegranulation is dried in the FBG until the target moisture content (≦1%by weight water) is reached. The granulation is milled through a 7 meshscreen and transferred to a tote blender or a V-blender. The requiredamount of antioxidant, butylated hydroxytoluene (0.08%), is sizedthrough a 60 mesh screen. The required amount of lubricant, stearic acid(0.25%), is sized through a 40 mesh screen and both materials areblended into the granulation using the tote or V-blender until uniformlydispersed (about 1 minute for stearic acid and about 10 minutes forBHT).

Bilayer Core Compression

A longitudinal tablet press (Korsch press) is set up with round, deepconcave punches and dies. Two feed hoppers are placed on the press. Thedrug layer prepared as above is placed in one of the hoppers while theosmotic push layer prepared as above is placed in the remaining hopper.

The initial adjustment of the tableting parameters (drug layer) isperformed to produce cores with a uniform target drug layer weight. Thesecond layer adjustment (osmotic push layer) of the tableting parametersis performed which bonds the drug layer to the osmotic layer to producecores with a uniform final core weight, thickness, hardness, andfriability. The foregoing parameters can be adjusted by varying the fillspace and/or the force setting. A typical tablet containing a targetamount of drug may be approximately 0.465 inches long and approximately0.188 inches in diameter.

Preparation of the Subcoat Solution and Subcoated System

The subcoat solution is prepared in a covered stainless steel vessel.The appropriate amounts of povidone (K29-32) (2.4%) and hydroxypropylcellulose (MW 80,000) (Klucel EF, Aqualon Company) (5.6%) are mixed intoanhydrous ethyl alcohol (92%) until the resulting solution is clear. Thebilayer cores prepared above are placed into a rotating, perforated pancoating unit. The coater is started and after the coating temperature of28 -36° C. is attained, the subcoating solution prepared above isuniformly applied to the rotating tablet bed. When a sufficient amountof solution has been applied to provide the desired subcoat weight gain,the subcoat process is stopped. The desired subcoat weight will beselected to provide acceptable residuals of drug remaining in the dosageform as determined in the release rate assay for a 24-hour period.Generally, it is desirable to have less than 10%, more preferably lessthan 5%, and most preferably less than 3% of residual drug remainingafter 24 hours of testing in a standard release rate assay as describedherein, based on the initial drug loading. This may be determined fromthe correlation between subcoat weight and the residual drug for anumber of dosage forms having the same bilayer core but differentsubcoat weights in the standard release rate assay.

Preparation of the Rate Controlling Membrane and Membrane Coated System

Subcoated bilayer cores prepared as above are placed into a rotating,perforated pan coating unit. The coater is started, and after thecoating temperature (28-38° C.) is attained, a coating solution such asillustrated in A, B or C below is uniformly applied to the rotatingtablet bed until the desired membrane weight gain is obtained. Atregular intervals throughout the coating process, the weight gain isdetermined and sample membrane coated units may be tested in the releaserate assay to determine a T₉₀ for the coated units. Weight gain may becorrelated with T₉₀ for membranes of varying thickness in the releaserate assay. When sufficient amount of solution has been applied,conveniently determined by attainment of the desired membrane weightgain for a desired T₉₀, the membrane coating process is stopped.Illustrative rate controlling membrane compositions:

A. A coating solution is prepared in a covered stainless steel vessel.The appropriate amounts of acetone (5650 g) and water (297 g) are mixedwith the poloxamer 188 (16 g) and cellulose acetate (297 g) until thesolids are completely dissolved. The coating solution has about 5%solids upon application.

B. Acetone (5054 g) is mixed with cellulose acetate (277.2 g) until thecellulose acetate is completely dissolved. Polyethylene glycol 3350 (2.8g) and water (266 g) are mixed in separate container. The two solutionsare mixed together until the resulting solution is clear. The coatingsolution has about 5% solids upon application.

C. Acetone (7762 g) is mixed with cellulose acetate (425.7 g) until thecellulose acetate is completely dissolved. Polyethylene glycol 3350 (4.3g) and water (409 g) are mixed in separate container. The two solutionsare mixed together until the resulting solution is clear. The coatingsolution has about 5% solids upon application.

Drilling of Membrane Coated Systems

One exit port is drilled into the drug layer end of the membrane coatedsystem. During the drilling process, samples are checked at regularintervals for orifice size, location, and number of exit ports.

Drying of Drilled Coated Systems

Drilled coated systems prepared as above are placed on perforated oventrays which are placed on a rack in a relative humidity oven at 40° C.(43-45% relative humidity) and dried to remove the remaining solventsfrom the coating layers.

Color and Clear Overcoats

Optional color or clear coats solutions are prepared in a coveredstainless steel vessel. For the color coat 88 parts of purified water ismixed with 12 parts of Opadry II [color not critical] until the solutionis homogeneous. For the clear coat 90 parts of purified water is mixedwith 10 parts of Opadry Clear until the solution is homogeneous. Thedried cores prepared as above are placed into a rotating, perforated pancoating unit. The coater is started and after the coating temperature isattained (35-45° C.), the color coat solution is uniformly applied tothe rotating tablet bed. When sufficient amount of the dispersion hasbeen applied, as conveniently determined when the desired color overcoatweight gain has been achieved, the color coat process is stopped. Next,the clear coat solution is uniformly applied to the rotating tablet bed.When sufficient amount of solution has been applied, or the desiredclear coat weight gain has been achieved, the clear coat process isstopped. A flow agent (e.g., Car-nu-bo wax) is applied to the tablet bedafter clear coat application.

Variations in the foregoing procedure will be apparent to one skilled inthe art. The examples are provided to illustrate representative dosageforms of the invention prepared by analogous methods.

ASSAY

The release rate of drug from devices containing the dosage forms of theinvention may be determined in standardized assays such as thefollowing. The method involves releasing systems into a release liquidmedium, such as acidified water (pH 3), artificial gastric fluid orartificial intestinal fluid. Aliquots of sample release rate solutionsare injected onto a chromatographic system to quantify the amount ofdrug released during specified test intervals. Drug is resolved on a C18column and detected by UV absorption at the appropriate wavelength forthe drug in question. Quantitation is performed by linear regressionanalysis of peak areas from a standard curve containing at least fivestandard points.

Samples are prepared with the use of a USP Type 7 Interval ReleaseApparatus. Each system (invention device) to be tested is weighed. Then,each system is glued to a plastic rod having a sharpened end, and eachrod is attached to a release rate dipper arm. Each release rate dipperarm is affixed to an up/down reciprocating shaker (USP Type 7 IntervalRelease Apparatus), operating at an amplitude of about 3 cm and 2 to 4seconds per cycle. The rod ends with the attached systems arecontinually immersed in 50 ml calibrated test tubes containing 50 ml ofthe release medium, equilibrated in a constant temperature water bathcontrolled at 37° C.±0.5° C. At the end of each time interval specified,typically one hour or two hours, the systems are transferred to the nextrow of test tubes containing fresh release medium. The process isrepeated for the desired number of intervals until release is complete.Then the solution tubes containing released drug are removed and allowedto cool to room temperature. After cooling, each tube is filled to the50 ml mark, each of the solutions is mixed thoroughly, and thentransferred to sample vials for analysis by high pressure liquidchromatography (“HPLC”). Standard solutions of drug are prepared inconcentration increments encompassing the range of 5 micrograms to about400 micrograms and analyzed by HPLC. A standard concentration curve isconstructed using linear regression analysis. Samples of drug obtainedfrom the release test are analyzed by HPLC and concentration of drug isdetermined by linear regression analysis. The amount of drug released ineach release interval is calculated. Alternatively, concentration ofdrug may be determined by uv analysis.

EXAMPLE 1

A delivery system (FIG. 3) is manufactured for dispensing a beneficialdrug progesterone in a controlled manner over a prolonged period oftime. A self-emulsifying drug solution comprising, in weight percent, 2%progesterone, 49% polyoxyl 35 castor oil (Cremophor EL, BASFCorporation) and 49% distilled acetylated monoglyceride (Myvacet 9-45)is prepared. Then, 38% of the solution is blended with 47% of porouscalcium hydrogen phosphate (FujiCalin SG) in a mixing vessel. Fourpercent of hydroxypropyl methylcellulose (HPMC E5) dissolved in ethanolis slowly added into the mixing vessel containing the blend, and ismixed with the blend until even consistency of wet mass is attained. Thewet mass is passed through a screen and then dried at ambient conditionsovernight. The mass is rescreened, and then 10% of maltose and 1%magnesium stearate is added to the granules and blended.

Next, an osmotic-layer forming composition comprising, in weightpercent, 58.75% sodium carboxymethyl cellulose (7H4F), 30.0% sodiumchloride, 5.0% hydroxpropyl methylcellulose (E5), 1.0% red ferric oxideis prepared by passing each component a 40-mesh stainless steel screenand then blending in a Galtt fluid-bed granulator and sprayed with 5.0%hydroxypropyl cellulose (EF) solution in purified water untilhomogeneous granules form. These granules are passed through an 8-meshstainless steel screen and mixed with 0.25% magnesium stearate. 376 Mgof the drug-layer granules and 169 mg of the osmotic(push)-layergranules are compressed into bi-layer longitudinal caplets using0.265″round punch and Carver press. Prior to compression, a small amountof mannitol is placed on the drug layer composition to facilitateejection of the tablets from the tooling. The tablets are coated with asubcoat composition comprising 5% of Klucel JF and 95% of ethanol usinga Freud Hi-coater. The weight of the subcoat is about 3 mg. Then, thesubcoated tablets are coated with a rate-controlling membranecomposition. The membrane-forming composition comprises, in weightpercent, 85% cellulose acetate having an acetyl content of 39.8% and 15%Pluronic F68. The membrane-forming composition is dissolved in acetoneto make a 5% solid solution. The membrane-forming composition is sprayedonto the tablets in a Freud Hi-coater. The membrane weight is about 22mg. Finally, an exit orifice (230 mil) is cut mechanically on thedrug-layer side of the system. The final system delivers progesteronein-vitro with a zero order delivery as shown in FIG. 5.

EXAMPLE 2

A delivery system (FIG. 4) is manufactured for dispensing a beneficialdrug progesterone as a delayed pulse. First, a self-emulsifying drugsolution comprising, in weight percent, 2% progesterone, 49% CremophorEL and 49% Myvacet 9-45 is prepared. Then, 38% of the solution isblended with 47% of porous calcium hydrogen phosphate (FujiCalin SG)in amixing vessel. Four percent of HPMC E5 dissolved in ethanol is slowlyadded into the mixing vessel containing the blend, and is mixed with theblend until even consistency of wet mass is attained. The wet mass ispassed through a screen and then dried at ambient conditions until thegranulation reaches the specified moisture level. The mass isrescreened, and then 10% of maltose and 1% magnesium stearate is addedto the granules and blended.

Next, an osmotic (push)-layer forming composition comprising, in weightpercent, 58.75% sodium carboxymethyl cellulose (7H4F), 30.0% sodiumchloride, 5.0% hydroxpropyl methylcellulose (E5), 1.0% red ferric oxideis prepared by passing each component a 40-mesh stainless steel screenand then blending in a Galtt fluid-bed granulator and sprayed with 5.0%hydroxypropyl cellulose (EF) solution in purified water untilhomogeneous granules form. These granules are passed through an 8-meshstainless steel screen and mixed with 0.25% magnesium stearate.

Then, 50 mg of placebo-layer granules (having the same composition asthe osmotic-layer), 195 mg of the drug-layer granules and 165 mg of theosmotic-layer granules are compressed into tri-layer longitudinalcaplets using 0.265″ round punch and Carver press. The tablets arecoated with a subcoat composition comprising 5% of Klucel JF and 95% ofethanol using a Freud Hi-coater. The weight of the subcoat is about 3mg. Then, the subcoated tablets are coated with a rate-controllingmembrane composition. The membrane-forming composition comprises, inweight percent, 85% cellulose acetate having an acetyl content of 39.8%and 15% Pluronic F68. The membrane-forming composition is dissolved inacetone to make a 5% solid solution. The membrane-forming composition issprayed onto the tablets in a Freud Hi-coater. The membrane weight isabout 22 mg. Finally, an exit orifice (230 mil) is cut mechanically onthe 1st placebo-layer side of the system. The final system deliversprogesterone in-vitro with a 2 hour delayed pulse as shown in FIG. 6.

EXAMPLE 3

The procedure of Example 2 is repeated in this example for providing thefollowing dosage form:

A dosage form composed of the drug-layer, osmotic-layer and themembrane, the compositions of which are all identical to those inExample 2 is prepared, except that the placebo-layer weight is 100 mg.The final dosage form delivers progesterone in-vitro with a 3 hourdelayed pulse as shown in FIG. 7.

EXAMPLE 4

The procedure of Example 2 is repeated in this example for providing thefollowing dosage form:

A dosage form composed of the drug-layer, osmotic-layer and themembrane, the compositions of which are all identical to those inExample 2 is prepared, except that the placebo-layer weight is 155 mg.The final dosage form delivers progesterone in-vitro with a 5 hourdelayed pulse as shown in FIG. 8.

EXAMPLE 5

The procedure of Example 2 is repeated in this example for providing thefollowing dosage form:

A dosage form composed of the drug-layer, osmotic-layer and themembrane, the compositions of which are all identical to those inExample 2 is prepared, except that the placebo-layer weight is 250 mg.The final dosage form delivers progesterone in-vitro with a 6-7 hourdelayed pulse as shown in FIG. 9.

EXAMPLE 6

The procedure of Example 2 is repeated in this example for providing thefollowing dosage form:

A dosage form composed of the osmotic-layer and the membrane layercompositions which are identical to those in Example 2 is prepared,except that the placebo-layer weight is 155 mg, the drug-layergranulation is composed of 36% of the drug solution described in Example2, 44% calcium phosphate, 4% HPMC E5, 1% Mg stearate and 15% maltose,and the weight of the rate-controlling membrane is 105 mg. The finaldosage form delivers progesterone in-vitro with a 10-h delayed pulse asshown in FIG. 10.

EXAMPLE 7

The following formulations are prepared for incorporation into thedosage forms illustrated in FIG. 3 and FIG. 4 in accordance with thegeneral procedures described. All percentages are by weight unlessotherwise noted. The Polyox 303 push layer is used as the barrier ordelay layer (sometimes denoted as a placebo layer) for those dosageforms illustrated in FIG. 4 and as the expandable or push layer in bothdosage forms illustrated in FIGS. 3 and 4. Tableting is done on a Carverpress at a force of one-quarter ton.

Polyox 303 push and delay layer formulation Polyox 303 63.68% SodiumChloride 30% HPMC E5 5% Red Ferric Oxide 1% Mg Stearate 0.25% BHT 0.08%

Polyox 303 Preparation:

The Polyox, NaCl, and oxide are blended in a Glatt fluid-bed granulatorand sprayed with a 5% HPMC E5 solution in purified water untilhomogeneous granules are formed. These granules are passed through a16-mesh stainless steel screen and mixed with magnesium stearate andBHT.

FujiCalin formulations for drug tablet dissolution Formulation A B C D EFujiCalin SG 52% 52% 47% 47% 44% Cremophor EL — 20.6% 18.6% 18.6% 17.6%Cremophor RH 20.6% — — — — Myvacet 9-45 20.6% 20.6% 18.6% 18.6% 17.6%Progesterone 0.84% 0.84% 0.76% 0.76% 0.72% HPMC E5 4.96% 4.96% 4.04%4.04% 4.08% PVP XL — — 10% — 15% Maltose — — 10% — Mg Stearate 1% 1% 1%1% 1%

Fujicalin Tablet Preparation:

The progesterone, Cremophor and Myvacet are dissolved by combining thematerials in a mixing bowl and mixing with a magnetic stir bar in a 40Cwater bath for 3 hours. The resulting solution is slowly added to theFujiCalin granules in a mechanical mixing bowl (KitchenAid mixer) whilemixing. Mixing is continued for 10 minutes and the HPMC E5, wetgranulated with ethanol, is added. The resulting mass is passed througha 20-mesh screen and allowed to dry overnight under ambient conditions.The dried material is again screened through a 20-mesh screen, and thedried granules are blended with the PVP XL on a roller mixer for 10minutes. Then, the magnesium stearate is added, and the mixture isblended on the roller mixer for an additional 2 minutes. The resultingmaterial is suitable for tableting. To facilitate release of the tabletsfrom the die components, a small amount of mannitol may be applied tothe outside surface of the drug formulation being tableted. Tableting isdone on a Carver press at a force of one-quarter ton.

The dissolution profiles for tablets containing the various drugformulations described above in artificial gastric fluid developed in aUSP bath are represented in FIG. 11, in which circles represent theformulation A, inverted triangles represent formulation B, squaresrepresent formulation C, diamonds represent formulation D, and trianglesrepresent formulation F.

Pulse System Tableting:

Tri-layer tablets containing the foregoing formulations and completeddosage forms are prepared according to the general procedures describedin Example 1. The dosage forms provide pulsed delivery of progesteronehaving varying delay periods depending on the amount of the material inthe placebo/barrier layer.

Neusilin formulations for drug tablet Formulation G/K H/L I/M J NeusilinUS2 34% 36% 38% 40% Cremophor EL 24.99% 26.46% 27.93% 29.4% Myvacet 9-4524.99% 26.46% 27.93% 29.4% Progesterone 1.02% 1.08% 1.14% 1.2% Ac-Di-Solor PVP XL 15% 10% 5% 0%

Neusilin tablet preparation:

Neusilin tablets having formulations as set forth above are prepared ina similar manner to that described for FujiCalin above except that themagnesium stearate and its mixing step are eliminated. Formulations G,H, and I are formed with Ac-Di-Sol. Formulations K, L, and M are formedwith PVP XL. Tableting is done on a Carver press at a force ofone-quarter ton. Tablets are readily ejected from the die without theuse of mannitol. The dissolution profiles for the various formulationsare represented in FIG. 12. The filled circles represent formulation G,filled, inverted triangles represent formulation H, and filled squaresrepresent formulation I. The open circles represent formulation K, open,inverted triangles represent formulation L, and open squares representformulation M. The filled diamonds represent formulation J.

Pulse System Tableting:

Tri-layer tablets are prepared by the general procedures described inExample 1, and coated with a semipermeable membrane of celluloseacetate/Pluronics F68 at a weight ratio of 85115 as described.Representative release profiles for the tri-layer, pulse dosage formsare illustrated in FIG. 13 for formulations as described above with 5%Acdisol, and barrier/membrane layer weights of 50/15 mg, 250/22 mg, and155/61 mg, providing delay periods of about 1, 5 and 10 hours,respectively.

EXAMPLE 8

This example illustrates that the dosage forms may be tableted withconventional, automatic tableting equipment. Active agent was omittedfrom the liquid formulation sorbed into the porous particles because oflimitations on the use of drug with equipment that was being used inon-going operations. Since Cremophor EL could be assayed, it served thedual role of liquid formulation sorbed into particles and entity fordetermination of release from sample dosage forms. The particleformulation, without drug, is prepared as a 10 kg batch for use in atrilayer dosage form as illustrated in FIG. 4. The trilayer tablets areformed on a multi-station tri-layer tablet press having 11 stations. Thepress is operated at 5 rpm and the compression forces utilized for thefirst layer (osmotic push layer), second layer (placebo/particles) andthird layer (barrier) are 100, 100, and 4,000 N, respectively. Theweights in each tablet of the osmotic/placebo (particles)/barrier layersare 175/160/125 mg, respectively. Tablets prepared are expelled from thetableting cavity without sticking to the cavity walls or the punch.

The Following Formulation was Utilized for the Preparation of theMock-drug Layer:

Neusilin US2 55.8% Cremophor EL 18.6% Myvacet 9-45 18.6% Ac-Di-Sol 4.5%Stearic Acid 2.0% Mg Stearate 0.5%

Particle Layer Preparation:

The Cremophor and Myvacet are mixed in a large stainless steel pot witha mechanical mixer for 20 minutes. In a large Hobart mixer Neuslinpowder is added to the bowl, and the Cremophor/Myvacet blend is slowlyadded through a funnel to the powder over a 5 minute period whilestirring is maintained. Material on the sides of the bowl is scrapeddown and the blend is mixed for 2 minutes more. Then the material istransferred to a Gemco V-blender, and the Ac-Di-Sol and stearic acid areadded. The resulting mass is mixed for 5 minutes, after which themagnesium stearate is added and the mass mixed for 1 minute more. Theblended material flows easily and is may be directly loaded into thehoppers of the tableting press.

Tri-layer tablets prepared from the above formulation as the(drug)/particle layer and the Polyox formulation for the barrier andpush layers described above were prepared as described withsemipermeable membrane coats formed from 80/20 celluloseacetate/Pluronics F68 of 20 mg, 31 mg, 41 mg and 57 mg and a 190 milexit orifice. The release profiles (measured in terms of Cremophorreleased since no drug was present) of those systems are presented inFIG. 14. The filled circles correspond to a 20 mg membrane coat, filled,inverted triangles correspond to a 31 mg membrane coat, filled squarescorrespond to a 41 mg membrane coat, and filled diamonds correspond to a57 mg membrane coat.

The present invention is described and characterized by one or more ofthe following technical features and/or characteristics, either alone orin combination with one or more of the other features andcharacteristics: a dosage form for an active agent comprising a walldefining a cavity, the wall having an exit orifice formed or formabletherein and at least a portion of the wall being semipermeable; anexpandable layer located within the cavity remote from the exit orificeand in fluid communication with the semipermeable portion of the wall; adrug layer located within the cavity adjacent the exit orifice and indirect or indirect contacting relationship with the expandable layer;the drug layer comprising a liquid, active agent formulation absorbed inporous particles, the porous particles being adapted to resistcompaction forces sufficient to form a compacted drug layer withoutsignificant exudation of the liquid, active agent formulation, thedosage form optionally having a placebo layer between the exit orificeand the drug layer; a dosage form comprising a flow-promoting layerinterposed between the inner surface of the wall and at least theexternal surface of the drug layer located within the cavity; a dosageform for an active agent comprising a wall defining a cavity, the wallhaving an exit orifice formed or formable therein and at least a portionof the wall being semipermeable; an expandable layer located within thecavity remote from the exit orifice and in fluid communication with thesemipermeable portion of the wall; a drug layer located within thecavity adjacent the exit orifice and in direct or indirect contactingrelationship with the expandable layer; the drug layer comprising aliquid, active agent formulation absorbed in porous particles, theporous particles, having a mean particle size of 50-150 microns, beingformed by spray drying a scale-like calcium hydrogen phosphate with aspecific surface area of 20 m²/g to 60 m²/g, an apparent specific volumeof 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g or more, aprimary particle size of 0.1μ to 5μ, and an average particle size of 2μto 10μ among secondary particles that are aggregates of the primaryparticles, the scale-like calcium hydrogen phosphate being representedby the following general formula:

CaHPO₄.mH₂O

wherein m satisfies the relationship 0≦m≦0.5 or 0≦m≦2.0, the dosage formoptionally having a placebo layer between exit orifice and the druglayer; a dosage form for an active agent comprising a wall defining acavity, the wall having an exit orifice formed or formable therein andat least a portion of the wall being semipermeable; an expandable layerlocated within the cavity remote from the exit orifice and in fluidcommunication with the semipermeable portion of the wall; a drug layerlocated within the cavity adjacent the exit orifice and in direct orindirect contacting relationship with the expandable layer; the druglayer comprising a liquid, active agent formulation absorbed in porousparticles, the porous particles being calcium hydrogen phosphate havinga specific volume of at least 1.5 ml/g, a BET specific surface area ofat least 20 m²/g, and a water absorption capacity of at least 0.7 ml/g,the dosage form optionally having a placebo layer between the exitorifice and the drug layer; a dosage form for an active agent comprisinga wall defining a cavity, the wall having an exit orifice formed orformable therein and at least a portion of the wall being semipermeable;an expandable layer located within the cavity remote from the exitorifice and in fluid communication with the semipermeable portion of thewall; a drug layer located within the cavity adjacent the exit orificeand in direct or indirect contacting relationship with the expandablelayer; the drug layer comprising a liquid, active agent formulationabsorbed in porous particles, the porous particles being calciumhydrogen phosphate having a specific volume of at least 1.5 ml/g, a BETspecific area of at least 20 m²/g, and a water absorption capacity of atleast 0.7 ml/lg, the particles having a size distribution of 100% lessthan 40 mesh, 50%-100% less than 100 mesh and 10%-60% less than 200mesh, the dosage form optionally having a placebo layer between the exitorifice and the drug layer; a dosage form for an active agent comprisinga wall defining a cavity, the wall having an exit orifice formed orformable therein and at least a portion of the wall being semipermeable;an expandable layer located within the cavity remote from the exitorifice and in fluid communication with the semipermeable portion of thewall; a drug layer located within the cavity adjacent the exit orificeand in direct or indirect contacting relationship with the expandablelayer; the drug layer comprising a liquid, active agent formulationabsorbed in porous particles, the porous particles being calciumhydrogen phosphate having a bulk specific volume of 1.5 ml/g-5 ml/g, aBET specific area of 20 m²/g-60 m²/g, a water absorption capacity of atleast 0.7 ml/g, and a mean particle size of 50 microns or greater, thedosage form optionally having a placebo layer between the exit orificeand the drug layer; a dosage form for an active agent comprising a walldefining a cavity, the wall having an exit orifice formed or formabletherein and at least a portion of the wall being semipermeable; anexpandable layer located within the cavity remote from the exit orificeand in fluid communication with the semipermeable portion of the wall; adrug layer located within the cavity adjacent the exit orifice and indirect or indirect contacting relationship with the expandable layer;the drug layer comprising a liquid, active agent formulation absorbed inporous particles, the porous particles being adapted to resistcompaction forces sufficient to form a compacted drug layer withoutsignificant exudation of the liquid, active agent formulation, theporous particles being formed from material selected from calciumhydrogen phosphate, magnesium aluminometasilicates, microcrystallinecelluloses and silicon dioxides; a dosage form comprising at least twodrug layers separated by at least one inert layer; a dosage formcomprising at least two drug layers, each of said drug layers containinga different active agent; a method of facilitating the release of anactive agent from a dosage form comprising sorbing a liquid formulationof the active agent into a plurality of porous particles, the particles,having a mean particle size of 5-150 microns, being formed by spraydrying a scale-like calcium hydrogen phosphate with a specific surfacearea of 20 m²/g to 60 m²/g, an apparent specific volume of 1.5 ml/g ormore, an oil absorption capacity of 0.7 ml/g or more, a primary particlesize of 0.1μ to 5μ, and an average particle size of 2μ to 10μ amongsecondary particles that are aggregates of the primary particles, thescale-like calcium hydrogen phosphate being represented by the followinggeneral formula:

CaHPo₄.mH₂O

wherein m satisfies the relationship 0≦m≦0.5 or 0≦m≦2.0, and dispersingthe particles throughout a bioerodible carrier; a composition comprisinga liquid formulation of an active agent sorbed into a plurality ofporous particles, the particles being formed by spray drying ascale-like calcium hydrogen phosphate with a specific surface area of 20m²/g to 60 m²/g, an apparent specific volume of 1.5 ml/g or more, an oilabsorption capacity of 0.7 ml/g or more, a primary particle size of 0.1μto 5μ, and an average particle size of 2μ to 10μ among secondaryparticles that are aggregates of the primary particles, the scale-likecalcium hydrogen phosphate being represented by the following generalformula:

CaHPO₄.mH₂O

wherein m satisfies the relationship 0≦m≦0.5 or 0≦m≦2.0, and dispersedthroughout a bioerodible carrier, the particles being released in theenvironment of use over a prolonged period of time; a dosage formwherein the liquid, active agent formulation comprises aself-emulsifying formulation; a dosage form wherein the active agent haslow water solubility; a dosage form wherein the liquid, active agentformulation comprises an absorption enhancer; a dosage form wherein theliquid, active agent formulation comprises at least 30% by weight of thedrug layer; dosage form wherein the porous particle comprises magnesiumaluminometasilicate represented by the general formula

Al₂O₃MgO.2SiO₂.nH₂O

wherein n satisfies the relationship 0≦n≦10; a dosage form wherein theporous particle comprises magnesium aluminometasilicate represented bythe general formula

Al₂O₃MgO.2SiO₂.nH₂O

wherein n satisfies the relationship 0≦n≦10 and having a specificsurface area of about 100-300 m²/g, an oil absorption capacity of about1.3-3.4 ml/lg, a mean particle size of about 1-2 microns, an angle ofrepose about 25°-45°, a specific gravity of about 2 g/ml and a specificvolume of about 2.1-12 ml/g; a dosage form having placebo layer locatedbetween the drug layer and an exit orifice; a dosage form comprising apH regulating agent selected from organic acids, inorganic acids andbases; a dosage form comprising a chelating agent.

The above-described exemplary embodiments are intended to beillustrative in all respects, rather than restrictive, of the presentinvention. Thus, the present invention is capable of implementation inmany variations and modifications that can be derived from thedescription herein by a person skilled in the art. All such variationsand modifications are considered to be within the scope and spirit ofthe present invention as defined by the following claims.

What is claimed is:
 1. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the dosage form optionally having a placebo layer between the exit orifice and the drug layer.
 2. The dosage form of claim 1 comprising a flow-promoting layer interposed between the inner surface of the wall and at least the external surface of the drug layer located within the cavity.
 3. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being formed by spray drying a calcium hydrogen phosphate with a specific surface area of 20 m²/g to 60 m²/g, an apparent specific volume of 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g or more, a primary particle size of 0.1μ to 5μ, and an average particle size of 2μ to 10μ among secondary particles that are aggregates of the primary particles, the calcium hydrogen phosphate being represented by the following general formula: CaHPO₄.mH₂O wherein m satisfies the relationship 0≦m≦2.0, the dosage form optionally having a placebo layer between exit orifice and the drug layer.
 4. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being calcium hydrogen phosphate having a specific volume of at least 1.5 ml/g, a BET specific surface area of at least 20 m²/g, and a water absorption capacity of at least 0.7 ml/g, the dosage form optionally having a placebo layer between the exit orifice and the drug layer.
 5. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being calcium hydrogen phosphate having a specific volume of at least 1.5 ml/lg, a BET specific area of at least 20 m²/g, and a water absorption capacity of at least 0.7 ml/g, the particles having a size distribution of 100% less than 40 mesh, 50%-100% less than 100 mesh and 10%-60% less than 200 mesh, the dosage form optionally having a placebo layer between the exit orifice and the drug layer.
 6. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being calcium hydrogen phosphate having a bulk specific volume of 1.5 ml/g-5 ml/g, a BET specific area of 20 m²/g-60 m²/g, a water absorption capacity of at least 0.7 ml/g, and a mean particle size of 50 microns or greater, the dosage form optionally having a placebo layer between the exit orifice and the drug layer.
 7. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being adapted to resist compaction forces sufficient to form a compacted drug layer without significant exudation of the liquid, active agent formulation, the porous particles being formed from material selected from calcium hydrogen phosphate, magnesium aluminometasilicates, microcrystalline celluloses and silicon dioxides.
 8. The dosage form of claim 7 comprising a flow-promoting layer between the inner surface of the wall and at least the external surface of the drug layer located within the cavity.
 9. The dosage form of claim 7 comprising at least two drug layers separated by at least one inert layer.
 10. The dosage form of claim 7 comprising at least two drug layers, each of said drug layers containing a different active agent.
 11. A method of facilitating the release of an active agent from a dosage form comprising sorbing a liquid formulation of the active agent into a plurality of porous particles, the particles being selected from the group consisting of (i) particles formed by spray drying a calcium hydrogen phosphate with a specific surface area of 20 m²/g to 60 m²/g, an apparent specific volume of 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g or more, a primary particle size of 0.1μ to 5μ, and an average particle size of 2μ to 10μ among secondary particles that are aggregates of the primary particles, the calcium hydrogen phosphate being represented by the following general formula: CaHPO₄.mH₂O wherein m satisfies the relationship 0≦m≦2.0, and (ii) particles of magnesium aluminometasilicate represented by the general formula Al₂O₃MgO.2SiO₂.nH₂O wherein n satisfies the relationship 0≦n≦10 and having a specific surface area of about 100-300 m²/g, an oil absorption capacity of about 1.3-3.4 ml/g, a mean particle size of about 1-2 microns, an angle of repose about 25°-45°, a specific gravity of about 2 g/ml and a specific volume of about 2.1-12 ml/g; and dispersing the particles throughout a bioerodible carrier.
 12. A composition comprising a liquid formulation of the active agent sorbed into a plurality of porous particles and a bioerodible carrier, the particles being selected from the group consisting of (i) particles formed by spray drying a calcium hydrogen phosphate with a specific surface area of 20 m²/g to 60 m²/g, an apparent specific volume of 1.5 ml/g or more, an oil absorption capacity of 0.7 ml/g or more, a primary particle size of 0.1μ to 5μ, and an average particle size of 2μ to 10μ among secondary particles that are aggregates of the primary particles, the calcium hydrogen phosphate being represented by the following general formula: CaHPO₄.mH₂O wherein m satisfies the relationship 0≦m≦2.0, and (ii) particles of magnesium aluminometasilicate represented by the general formula Al₂O₃MgO.2SiO₂.nH₂O wherein n satisfies the relationship 0≦n≦10 and having a specific surface area of about 100-300 m²/g, an oil absorption capacity of about 1.3-3.4 ml/g, a mean particle size of about 1-2 microns, an angle of repose about 25°-45°, a specific gravity of about 2 g/ml and a specific volume of about 2.1-12 ml/g, and the particles being dispersed throughout the bioerodible carrier for release in the environment of use over a prolonged period of time.
 13. The dosage form of claim 1 wherein the liquid, active agent formulation comprises a self-emulsifying formulation.
 14. The dosage form of claim 13 wherein the active agent has low water solubility.
 15. The dosage form of claim 1 wherein the liquid, active agent formulation comprises an absorption enhancer.
 16. The dosage form of claim 1 wherein the liquid, active agent formulation comprises at least 30% by weight of the drug layer.
 17. The dosage form of claim 1 wherein the porous particle is magnesium aluminometasilicate represented by the general formula Al₂O₃MgO.2SiO₂.nH₂O wherein n satisfies the relationship 0≦n≦10.
 18. A dosage form for an active agent comprising a wall defining a cavity, the wall having an exit orifice formed or formable therein and at least a portion of the wall being semipermeable; an expandable layer located within the cavity remote from the exit orifice and in fluid communication with the semipermeable portion of the wall; a drug layer located within the cavity adjacent the exit orifice and in direct or indirect contacting relationship with the expandable layer; the drug layer comprising a liquid, active agent formulation absorbed in porous particles, the porous particles being magnesium aluminometasilicate represented by the general formula Al₂O₃MgO.2SiO₂.nH₂O wherein n satisfies the relationship 0≦n≦10 and having a specific surface area of about 100-300 m²/g, an oil absorption capacity of about 1.3-3.4 ml/g, a mean particle size of about 1-2 microns, an angle of repose about 25°-45°, a specific gravity of about 2 g/ml and a specific volume of about 2.1-12 ml/g.
 19. The dosage form of claim 18 comprising a placebo layer located between the exit orifice and the drug layer.
 20. The dosage form of claim 18 wherein the drug layer comprises a bioerodible carrier.
 21. The dosage form of claim 1 wherein the drug layer comprises a pH regulating agent selected from organic acids, inorganic acids or bases.
 22. The dosage form of claim 1 wherein the drug layer comprises a chelating agent. 